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A ASF Amyloid-A Stimulating Factor (IL-1)
AP Anaphylatoxin
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BSF-2 B-Cell Stimulatory Factor-2 (Interleukin-6)
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CFU-MEG Colony Forming Unit-Megakaryocyte
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CSF Colony Stimulating Factor
CSF-1 Colony Stimulating Factor-1 (Macrophage-Colony Stimulating Factor)
CRF Corticotropin Releasing Factor
CTLL IL-2 responsive T-cell line, CTLL-2/CT-6, used in second part of IL-1 assay213b.
D-10 IL-1/lectin responsive T-cell line

DAG Diacylglycerol
DEP Diethylpyrocarbonate

EGF Epidermal Growth Factor
EHAA Eagle's Hank's Amino Acid (Bruff)

EP Endogenous Pyrogen (Interleukin-1)
FBS Fetal Bovine Serum

FGF Fibroblast Growth Factor
G-CSF Granulocyte-Colony Stimulating Factor
GBE Glucocorticoid Binding Element
GM-CSF Granulocyte-Macrophage Colony Stimulating Factor
GRE Glucocorticoid Response Element
GP Granulocyte Pyrogen (Interleukin-1)

H-l Hemopoetin-1 (Interleukin-1)
HAF Hepatocyte Activating Factor (Interleukin-1)

HGF Hybridoma Growth Factor (Interleukin 6)1
HSF Hepatocyte Stimulatory Factor (Interleukin-6)

iv
IGF-1 Insulin-like Growth Factor-1
IFN-OC Interferon-alpha
IFN-y Interferon-gamma
IL-1 Interleukin-1 (LAF,LEM,HAF,H-1 ,GP,EP)
IL-1R Interleukin-1 receptor
IL-2 Interleukin-2 (T-cell Growth Factor)
IL-3 Interleukin-3 (Multi-Colony Stimulating Factor)

IL-4 Interleukin-4 (BCGF-1, BSF-1)
IL-5 Interleukin-5 (BCGF-2, Eosinophil Differentiaion Factor)
IL-6 Interleukin-6 (HSF, BCF-2)
IL-7 Interleukin-7, a stromal cell derived growth factor for pre-B and T cells

IL-8 Interleukin-8 (Neutrophil Activation/Attractive Protein-1)
IP3 Inositol triphosphate
LAF Lymphocyte Activating Factor (IL-1)

LAK Lymphokine Activated Killer cells
LBRM T-cell Lymphoma line, LBRM 33-1A5.47, used in first part of IL-1 assay213*3.
LEM Leukocyte Endogenous Mediator (EL-1)

LPS Lipopolysaccharide
M-CSF Macrophage-Colony Stimulating Factor
NGF Nerve Growth Factor

OAFs Osteoclast Activating Factors (Includes IL-13 and TNF-B)
PBS Phosphate Bufered Saline
PC Phosphotidylcholine
PDGF Platelet-derived Growth Factor
PI Phosphotidylinositol
PIP2 Phosphotidylinositol diphosphate

PKA Protein kinase A
PKC Protein kinase C
PM A Phorbol 12-myristate 13-acetate
PTH-R Parathyroid hormone receptor

PTHrP Parathyroid Hormone Related Protein
rhIL-2 Recombinant human Interleukin-2
Synergen Molecule which synergizes with TGF-6 for cytokine release
TGF-a Transforming Growth Factor-Alpha
TGF-13 Transforming Growth Factor-Beta
TBP

Transforming Growth Factor Binding Protein
TGFR-6 Receptor for Transforming Growth Factor-Beta
TIE

Transforming Growth Factor Inhibitory Element
TNF-a Tumor Necrosis Factor alpha
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For bone is not made of wood, indeed not stone, but wondrous things.
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I. ABSTRACT

Osteoblast activities include bone formation, osteoclast regulation, and
the secretion of a class of hormones called cytokines. Osteoblast-derived
cytokines include Interleukin-6 (IL-6) and two colony stimulating factors
(CSFs): Granulocyte-Macrophage CSF (GM-CSF), and Macrophage-CSF
(M-CSF).

Osteoblasts secrete cytokines after exposure to several well-

characterized

mitogens

such

as

lipopolysaccharide

phytohemagglutinin (PHA), and Interleukin-1.

(LPS),

What roles osteoblast-

derived cytokines play in normal bone remodeling is unknown.
Transforming Growth Factor-Beta (TGF-B) is a ubiquitous 23-25 kDa
homodimeric protein stored in platelets and bone.

TGF-B was originally

discovered as an inducer of neoplastic transformation in normal fibroblasts
but has since been implicated in matrix homeostasis, immunomodulation,
development and hematopoesis. Bone is the body's largest source of TGFB and the protein becomes activated after osteoclast bone resorption. No
definitive role for TGF-B in bone remodeling is known.
This thesis presents experiments which tested the effect of TGF-B on
osteoblast cytokine production and release.

Data from in vitro cytokine

assays of conditoned media suggest that TGF-B upregulates IL-6 and GMCSF secretion through a novel synergistic interaction with other low
concentration molecules including LPS, IL-1, and parathyroid hormone
(PTH), as a group referred to here as synergens.

M-CSF secretion was

unaffected by TGF-B alone or in combination with any synergen. 90% of
the GM-CSF and IL-6 release observed is achieved between 2.5 and
hours after exposure to TGF-B and a given synergen.

6

Furthermore, the

synergy between TGF-B and a given molecule is TGF-B-dependent. The

osteoblast response was not altered by exposure to indomethacin. RNA
analysis suggested that the synergy between TGF-6 and IL-1 may involve
TGF-6 upregulation of the IL-1 cell surface receptor. These observations
are the first to implicate TGF-B as a stimulatory molecule for cytokine
release from osteoblasts and suggest new aspects of bone remodeling as
well as a possible role for the osteoblast in hematopoesis.

II. INTRODUCTION Growth factors and essential principles;
The Discovery of Transforming Growth Factor-B; Osteoblast-derived cytokines;
Thesis investigation.
Throughout the life of the normal cell, there exists a tightly
controlled series of programs designed to insure the orderly and
regulatable growth and proliferation of the cell.

These controls

have enabled cells to survive the environmental fluctuations
throughout evolution and everyday life: Cells survive starvation by
slowing growth to minimal levels and cells maximize growth in
environments consistent with growth. At any given moment, a cell
must be aware of both its internal state as well as the external world.
Without normal growth and proliferation controls, there can be dire
consequences: An inability to respond appropriately to favourable
environmental

stimuli could result in decreased cell growth and

premature senescence. Alternatively, an inability to check growth
and to maintain quiescence, could result in inappropriate, sustained,
and non-suppressable growth, an extreme condition known as cancer.
Understanding how normal cells control the transitions
between the states of quiescence and growth is paramount towards
understanding why certain cells, i.e. neoplastic cells, cannot control
these transitions (Figure II.i).

The evolution of multicellular life

presented a particular problem for cellular growth.

Multicellular

organisms required each cell to regulate growth in a manner
appropriate to the growth of surrounding cells.

How cells

communicate to ensure such regulation is exceedingly complex and
has intrigued investigators for at least 70 years. In 1916, Australian
Brailsford Robertson (Figure II.ii) discovered that a murine

4

pituitary extract stimulated the growth of juvenile mice.

Robertson

purified a substance capable of achieving the same effect, a substance

Figure ILi. Normal and abnormal cellular growth pathways. When presented with
an environment devoid of growth signals normal cells respond by entering the
quiescent state of Go (a). Neoplastic cells, however, may continue to proliferate
irregularly (b). An environment replete with growth signals may induce normal
cells to divide regularly (c), whereas abnormal cells may either grow unchecked as
a neoplasia (di) or cease growth and enter Go (d2).

he called tethelin.^

At the same time, J. M. Byrne and Eric

Horning of Melbourne, Australia were attempting to grow
mammalian cells in vitro using tissue extracts from normal and
neoplastic tissue82.

In 1929, after Byrne and Homing published

their findings in the Australian Journal of Science, Robertson eagerly
sent Byme and Homing samples of tethelin to test on their in vitro
cultures.

Working with chick enterocytes, cells cultured in the

presence of tethelin grew faster than enterocytes cultured in chick
plasma alone22.

The significance of tethelin and tissue extracts

towards the growth of cells was immediately appreciated and tethelin
was accepted as the first 'growth factor' determined through in vitro

analysis.

The daunting task had only begun, however, in

determining what specifically a ’growth factor' was,

how growth

factors worked, and what role(s) the factors played in normal in vivo
physiology.
Upon Robertson's death in 1929 and Homing's departure from
Australia shortly thereafter these early efforts unfortunately came to
a halt. In 1951, growth factor work eventually resumed when Rita
Levi-Montalcini and

Stanley Cohen (figure II.ii) isolated nerve

growth factor (NGF) and epidermal growth factor (EGF)45T26
The characterization of these two molecules spawned a renewed and
intense effort to understand growth factor biology and growth factor

Figure Il.ii. Pioneers in growth factor research. Australian T. Brailsford Robertson
(1884-1930), left, isolated the first 'growth factor' from mouse pituitaries which he
called tethelin (Greekr’growing') a molecule whose identity is still undetermined.
Rita Levi-Montalcini (bom 1909), top right, and Stanley Cohen (born 1922),
bottom right, both received Nobel prizes for medicine in 1986 for their work on
Nerve Growth Factor and Epidermal Growth Factor, respectively, the first two
Nobel laureates in the growth factor field.

roles in physiology, guided by the ultimate goal of utilizing in vivo
growth factor capabilities for clinical needs. By 1963, several new
growth factors were isolated including Fibroblast Growth Factor
(FGF), Platelet-Derived Growth Factor (PDGF) and Insulin-like
Growth Factors 1 and 2 (IGFs-1 and -2).

In 1972,

Gery et al.

isolated Lymphocyte Activating Factor (LAF) derived from
macrophages67,68<

Because LAF was derived from a type of white

cell, and functioned as a growth mediator between white cells, LAF
was eventually known as interleukin-l, or IL-1.

IL-1

stimulated

great interest not only because its potent T-cell stimulatory ability
seemed

immunologically relevant, but because IL-1 had other

functions not directly leading to the 'usual' processes of growth, such
as mitosis or proliferation.

IL-1 was, for example, observed to

stimulate cartilage resorption98, induce the intrinsic pathway of the
clotting cascade128, chemoattract acute phase cells100, and cause
profound

fever1 T24.

Furthermore, IL-1 induced T-cell growth by

inducing the synthesis of interleukin-2, or IL-2, originally known as
T-cell Growth Factor (TCGF)124. It appeared that certain growth
factors had diverse roles in homeostasis and disease states.

With

attention shifted to the immune system, many growth factors were
characterized which appeared to be specifically active in the growth
and activity of immune cells.

Molecules like Interleukin-2 were

joined with six other interleukins (interleukins-3 through 8) and the
Colony Stimulating Factors or CSFs: Granulocyte-Monocyte CSF
(GM-CSF), Granulocyte-CSF (G-CSF), and Macrophage-CSF (MC’SF).

Thus, a new class of growth factors were found which

promoted changes in cellular activity in addition to stimulating

growth. These factors became

broadly known as cytokines.

Investigators soon demonstrated that cytokines could not be limited
by activity or in source to cells of the immune system but could be
isolated from cells as diverse as astrocytesI32b? kidney epithelial
cells1370,

endometrium154’!67b?

and cells 0f bone87.

The roles

cytokines play in these and other systems is not definitively known.
Growth factor research was made even more intriguing with the
discovery of cytokines important to excessive growth and frank
neoplastic change. Such molecules include the Transforming Growth
Factors Alpha and Beta (TGF-a & TGF-B)5’62’166- These molecules
were orginally observed in 1983 to induce neoplastic transformation
in normal fibroblasts growing in soft agar.

Transforming Growth

Factors have generated great interest because of their possible role in
wound repair, tissue differentiation and matrix formation.
Transforming Growth Factor-6 (TGF-6) is decidedly unique
among cytokines, however, in that it has been generally regarded as
an inhibitory molecule of normal cells, often implicated in the
suppression of normal growth.
For example, Transforming Growth Factor-6 is 10,000100,000 times as immunosuppressive as cyclosporin-A9.

TGF-6 is

ubiquitous, is stored primarily in the matrix of bone and is active
only after release from binding proteins28’35,167,183
richest source of TGF-6 in the

body34,35

defined for TGF-6 in bone tissue biology.

Bone is the

but no clear role is yet
TGF-6 is now being

tested in clinical trials as an immunosuppressive adjuvant in
chemotherapy, and as a topical agent in wound healing9,167,183a#
The obvious importance of this molecule for clinical pursuits

necessitates a clear understanding of TGF-B’s actions in normal and
abnormal human physiology.

Figure Il.iii. Original observations for the existence of transforming growth
factors, (a) Supernatants from neoplastic fibroblasts were aspirated and (b) added
to cultures of normal fibroblasts in vitro. The normal fibroblasts, in turn, were
observed to undergo transformation (c) and assume the neoplastic phenotype of the
originally transformed cultures4.

As mentioned above, cytokines are made by diverse populations
of cells. Perhaps few cells in the body are as active in this regard as
the osteoblast, the cell that forms bone.

Evidence of cytokine

production by bone cells is well-established, but the roles cytokines
play in bone metabolism and bone resorption is unknown37^.
Recalling that TGF-B is stored in bone, is the body's largest source
of the cytokine, and bone resorptive processes can activate TGF-B,
one may question if there is a relationship between TGF-B and the

release of cytokines from osteoblasts. This thesis investigates the
ability of TGF-6 and other cytokines to modulate the release of the
known osteoblast-derived cytokines. To focus the implications of the
data presented in this work, short discussions of the cells, cytokines
and genes relevent to the interpretation of the data will be presented
as follows.

A. TRANSFORMING GROWTH FACTOR- BETA TGF-6 can
transform 'primed' cells; TGF-6 is produced ubiquitously and stored in bone;
There are multiple types of TGF-6s but TGF-61 is studied in the present work;
TGF-6 is normally latent but is activated by low/ high pH and specific enzymes.
It has long been conjectured that normal cells influence their own
growth by releasing particular autocrine hormones which, in turn,
stimulate the cell itself, or in a paracrine fashion, stimulate
neighboring cells. Cancer cells may support their growth, in part,
by over producing or responding inappropriately to

normal

autocrine hormones. Such a hypothesis gained credence when it was
observed that supernatants from certain retrovirally transformed
cells could transform previously normal fibroblasts growing in soft
agar (Figure Il.iii above)4’62’166. The supernatants, it was thought,
contained molecules produced by the transformed cells, which
stimulated the transformed cells' growth and induced transformation
in healthy cells.
The molecules were referred to as Transforming Growth Factors
(TGFs),

initiating

much effort towards

the

characterization of the still-theoretical material.

isolation

and

In 1983, several

workers eventually isolated two disparate proteins which had
conferred upon supernatants an ability to transform healthy

cells133b, One of the proteins, TGF-Alpha (TGF-a) was found to be
related to Epidermal Growth Factor (EGF) and had equal affinity
for the EGF-receptor as did EGF itself.

The second protein, TGF-

Beta (TGF-B) was unrelated to EGF and was a ligand for its own

Figure Il.iv. Growth factor induction of active growth cycles. Quiescent cells can
be activated into active growth after certain 'priming' events, initiated by Plateletderived Growth Factor (PDGF). Either Epidermal Growth Factor (EGF) or
Transforming Growth Factor-alpha (TGF-a) can then induce a cell to enter the first
part of Gi. Insulin-like Growth Factor-1 (IGF-1) continues the induction of a
normal cycle of growth. Cells exposed to TGF-B, however, may enter cell cycles
which are not soon terminated, but continue in the unchecked manner typical of
neoplastic growth.

receptor complex9!’ 167,183.

As illustrated in figure Il.iv, it was

found that cells could be transformed by the TGFs only after
promotion by factors normally present in serum, primarily PlateletDerived Growth Factor (PDGF), and Insulin-like Growth Factor-1
(IGF-1).

TGF-a could substitute for EGF because the molecules

were ligands for the

same receptor.

Once a cell had been thus

promoted, TGF-8 alone could induce transformation91. Workers
have since found that TGF-a is produced only by certain neoplastic
cells in vitro. TGF-6, however, is ubiquitous,

produced by many

normal cells, especially developing tissues and tissues undergoing
repair.

TGF-6 is present in high concentrations in platelets (1500

molecules per

cell)5»195

and in bone (>30 mg/kg)35,167? suggesting

that the molecule is important to soft tissue wound healing and
mineralized tissue remodeling. It is now appreciated that TGF-6 is
an important molecule in normal growth processes and that an
understanding of TGF-6 biology in vivo will have many implications
for basic science and clinical medicine. A great deal of information
concerning TGF-8 has been accumulated, a description of which is
beyond the scope of this work. A summary of the major elements of
TGF-6 biology relevent to the data presented in this thesis follows.

TGF-6 is a homodimeric protein, linked by sulfide bonds, with
a molecular weight of 23-25,000 Daltons. By 1985, it was realized
that several TGFs-6 existed, differing in messenger RNA and amino
acid length and source of isolation. The original TGF-8, and the one
studied in this thesis, was referred to as TGF-81, isolated from
human platelets195, where it is stored in alpha-type granules167.
TGF-62 was isolated from porcine platelets and bovine bone. TGFs63.5 have not yet been isolated, but tentative cDNAs for these

putative proteins have been identified in oocyte gene libraries73,183,
Depending on the TGF-8 subspecies, TGF-6 mRNAs range from
1.5-6.5 kilobases, with a processed message of approximately 1200

kilobases in length. The mRNAs are translated into 380-420 amino
acid TGF-B precursors which is cleaved on both the amino end and
the carboxyl end to yield a 180 a.a. product.

All TGF-Bs are

generally equivalent in activity, despite their structural differences
and, therefore, this discussion will refer to them all as TGF-B, unless
otherwise stated.

TGF-B

is active in many tissues, as will be

described shortly, but only after it has been released from a protein
complex known as TGF binding protein (TBP). As shown below in
figure II.v, cleavage of the last 112 amino acids from the carboxyl
end of the original protein produces a TGF-B homodimer. Cleavage
of the first 29 amino acids from the remnant precursor produces a
sulfide-linked dimer which in turn binds to the TGF-B.

The two

dimers are themselves covalently linked to a larger, 125-160 kDa
'modulator' protein167.
The roles of these proteins are not known, but Kanzaki et al.
found that the binding protein was not necessary for the latency of
TGF-B i.

Kanzaki suggests that the protein functions as a mediator

of targeting, supported by the observation that both the binding
protein, and the precursor protein both have the so-called "RGD"
sequence- a fibronectin/vitreonectin cellular recognition site
established by an Arginine-Glycine-Aspartic Acid triplet101.
TGF-B is released in its active form by low or high pH ( <4.0 or
>8.5) or by in vitro chaiotropic agents124’128.

TGF-B release in

vivo is most likely to be achieved, therefore, in microenvironments
capable of generating such pH gradients.

One site may be that of

healing wounds where platelet-derived TGF-B i could be activated by

1 3

Figure II.v. Cleavage forms of TGF-B. (A.) Two precursor molecules are cleaved
at sites indicated by arrows producing mature TGF-B and a large dimer to which the
dimer TGF-B is bound. A 125-160 kDa 'modulator protein' (mp) is, in turn,
bound to the two dimers, but a true function for the modulator protein is still
unknown. (B.) Free, mature TGF-B as a 75 kDa homodimer. (C.) Two TGF-B
molecules bound covalendy by alpha2-microglobulin (a2m), a proposed 'scavenger'
protein for TGF-B and other potent growth factors.

macrophage-derived sialidases, endoglycosidases,

and other

protonogenic proteases which can establish extremely low, local pH
gradients (<3.7).

A particularly unique site is that of resorption

lacunae in bone, where resident osteoclasts resorb bone by utilizing
basolateral proton pumps which can lower lacunar pH
approximately 3.0.
resorption

to

Since latent TGF-Bi is stored in bone,

can release many molecules of TGF-Bi directly into a

resorption lacuna while the low pH of the lacuna functions to activate
TGF-B itself152.

These mechanisms of TGF-B activation could

insure that a responsive cell will not be affected by TGF-B unless the
molecule is activated, as in conditions of inflammation, wound

healing, or bone resorption. This strategem insures that the potency
of TGF-B will be made manifest only where and when such a
molecule is neccessary.
Confirming the importance of activated TGF-B to its autocrine
and paracrine function are observations concerning a human lung
carcinoma cell line, A549.

A549 cells are some of the most active

producers of latent forms of TGF-B and express many TGF-B
receptors.

Active TGF-B, however, when added to A549 cells in

vitro, greatly inhibits cell growth, suggesting that A549 cells have
lost some ability to activate the TGF-B that the cells themselves
release199.

A cell, apparently, like the A549 cell, which releases

TGF-B and expresses receptors for the molecule, must also have
activating mechanisms to utilize any of the autocrine capablities
which TGF-B may confer.
TGF-B may be important in controlling cell growth by
regulating the activity of the retinoblastoma gene product, RB. The
retinoblastoma gene

product may function as a growth suppressor

because loss of function of the RB gene can lead to oncogenesis.
Reintroduction of the RB product into proliferating cells which do
not produce such product slows growth.

The activity of the RB

product is thought to be regulated post-translationally via protein
phosphorylation states: Underphosphorylated RB is associated with
growth-arrest and Gi whereas phosphorylated RB is found in S
phase and G2/M. TGF-B was found to inhibit RB phosphorylation.
SV40 virus large T antigen binds the RB product and this large T
antigen specifically inhibits the growth suppressive activity of TGFB!20.

Activated, processed TGF-B has been found to bind avidly to
alpha2-microglobulin, the 240 kDa serum protein.

Alpha2-

microglobulin, or other TGF-B binding serum proteins, may be one
of the physiologic 'scavenging' mechanisms whereby the availability
of activated TGF-6 is regulated (Figure II.v)198. TGF-B acts as a
ligand for two glycoprotein membrane-bound receptors and one
betaglycan glycosaminoglycan receptor. The glycoprotein receptors,
TGFR-B I and II, are thought to mediate the effects of TGF-B
whereas the betaglycan may function in pericellular TGF-B
presentation13315.
TGF-B is remarkedy pluripotent and its actions
greatly dependent on cell type and

on cells are

differentiation state, TGF-B

concentration, and the presence of other growth factors.

There has

been much work on how TGF-B affects the physiology of
hepatocytes185, myocytes and myocardial infarction159*189a/b,
steroid synthesis89, bone cells3*33, alveolar cells134, angiogenesis41,
and

development163.

Findings from this work have great

implications for both TGF-B research as well as clinical applications
of TGF-B, findings which can not be summarized in this forum.
What follows is, therefore, a description of TGF-B effects in systems
which are especially pertinent to this thesis.
TGF-B and the Immune System . Suppression of B- and T-cells;
Inhibition of IgG/IgM production; Antagonism of IL-1 and other growth factors;
Chemotactin and stimulant for macrophages.
TGF-B decreases B- and T-cell growth and clonal expansion,
decreases the generation of lymphokine-activated killer cells (LAKs),
and

decreases cytotoxic T-cell (CTL) growth58*!40.

Recently,

TGF-B has been found to inhibit thymocyte growth, especially

thymocyte growth induced and supported by Interleukin-7. In this
regard, TGF-B is immunosuppressive to the femto-molar range,
making TGF-G

10,000 to

cyclosporin- A9*114.

100,000 times as suppressive as

TGF-B is, however, remarkably pleiotropic.

While some reports describe TGF-B as a potent inhibitor of acute
arthritic events19, others describe TGF-B as a potent inducer of
synovial inflammation4’197^
TGF-B works to decrease antibody production of the IgG and
IgM classes yet increases production of the IgA classes44’106- The
hypothesis that TGF-B might function to increase the populations of
IgA-bearing cells along respiratory and gastrointestinal epithelium is
now being investigated197*1.

TGF-B anatagonizes many of the affects

of Interleukin 1 (IL-1), IL-2, and IL-3, Tumor Necrosis Factoralpha (TNF-a), and Interferon alpha (IFN-a) on cytotoxic T-cell
function and the development of Lymphocyte-Activated Killer Cells
(LAKs)58. TGF-B downregulates IL-l-induced IL-6 production by
human monocytes144.

Whereas TGF-B is generally inhibitory for lymphocyte function,
it tends to be stimulatory for macrophage and monocyte function.
TGF-B is a chemoattractant for monocytes and macrophages, and
increases macrophage membrane receptors for TNF-a, PDGF-AA,
Fibroblast Growth Factor (FGF), IL-1, TGF-a, and TGF-B
itself13°, 197a, 197b. TGF-B is also extremely potent in suppressing
the superoxide (O') respiratory burst of macrophages and
polymorphonuclear lymphocytes (PMNs), leaving the general
impression that TGF-B suppresses the destructive effects of

macrophages and acute cell activities while facilitating macrophagederived factor function and the processes of tissue repair191.
TGF-B and the Cell Matrix. Upregulation and support of matrix
proteins via three mechanisms.

Perhaps few other fields in TGF-B research have proven
intriguing as that of

as

cell matrix biology and how the molecule

regulates matrix formation and the activity of mesenchymal cells.
TGF-B, the "gadabout growth factor"9, was eventually assigned a role
that subserved many of its ostensibly disparate activities: the
upregulation of matrix proteins133c.

Three matrixogenic mechanisms

have been thus far studied:
(1) TGF-B increases matrix molecule production: TGF-B
induces the production of certain matrix proteins like collagen types I,
III, IV and V, fibronectin, thrombospondin, osteopontin, osteonectin,
SPARC, and chondroitin and dermatan sulfates2’41’131’1332’148’196.
TGF-B directly stimulates the promotors for a2(I) collagen as well as
fibronectin, an influence mediated by an NF-1 binding site49.
Furthermore, TGF-B directly increases fibronectin gene transcription.
Most recently, Heine et al. have shown that TGF-B co-localizes with
collagen I & III, fibronectin and glycosaminoglycans during lung
branching morphogenesis80. Such observations suggest that TGF-B
may be important in the regulation of matrix formation in development
as well as in mature stages of life.
(2) TGF-B increases receptors for matrix proteins: TGF-B
induces the expression of the matrix protein receptors classed as
Integrins, the transmembrane links between the extracellular and

intracellular worlds79’93’1332.
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(3) TGF-B inhibits matrix proteases:

TGF-B can both

inhibit the expression of enzymes which can degrade the matrix
proteins, as well as induce the production of enzymes which inhibit the
matrix-degrading enzymes57’164.

Inhibition of the matrix protease

transin, a member of the metalloproteinase family, has recently been

found to involve a specific sequence in the transin gene promotor, the
TGF-6 inhibitory element (TIE)10**,134,135. After TGF-B stimulation
of the cell, the TIE sequence is bound by a trans-activating factor
containing the c-fos protein, fos, thus implicating the c-fos oncogene as
a mediator of TGF-B function in both cis- and trans-inhibition of
transin gene expression and thus of matrix regulation 108.
TGF-B and Bone. TGF-B is stored in bone; TGF-B is activated by
osteoclasts; TGF-B may promote bone formation via several mechanisms; TGF-B may
upregulate osteoblast cytoskeletal proteins.
TGF-B is stored primarily in two locations in the body: in the
alpha granules of platelets and in the matrix of bone33’55.

There are

approximately 1500 TGF-B molecules per platelet making platelets the
richest source of the hormone. TGF-B in bone, however, is dispersed
equally throughout the body skeleton making bone the largest source of
TGF-B in the body (0.3 mg/kg)179. While platelet-derived TGF-B has
been postulated to have roles in tissue repair, bone-derived TGF-B is
thought to have roles in the regulation of bone remodeling, the
continuous life-long process of resorbing and replacing bone with new
mineralized tissue.

Embryologically, TGF-B is actively expressed in

the axial skeleton and, in older embryos, in the cytoplasm of osteoblasts
involved in ossification processes30.
Osteoblasts

and certain osteosarcoma cells, have very high

messenger RNA levels for TGF-B, and secrete high concentrations of

the hormone28’35. Recalling that TGF-B is generally inhibitory for the
growth of normal cells,

it is surprising to observe that TGF-B is

mitogenic for osteoblasts and inhibitory for osteoclasts, suggesting a
pro-bone forming effect of the hormone33’24’47’157.

These effects

appear independent of prostaglandin production130. Mackie et al. have
described a TGF-B-induced increase in bone formation while Chenu et
al. have suggested that TGF-B acts as a chemotactic agent for osteoblast
migration into a remodeling locus42’130. Although TGF-B upregulates
extracellular matrix formation 158, Lomri et al. have shown that TGF-B
can increase intracellular cytoskeletal proteins as well127.

TGF-B

upregulates collagens I & III production3 but inhibits production of
collagen type II88. Particularly relevent to in vivo physiology of the
hormone is the observation that osteoclasts activate TGF-B from its
latent form when the hormone is released from the bone matrix. The
activated TGF-B may then, in high local concentrations, upregulate the
restoration of bone removed by the

osteoclasts which activated the

hormone.
The Bone Morphogenetic Proteins (BMPs) are important
hormones in osteogenesis and development and belong to the TGF-B
superfamily. BMP-2B is a known inducer of endochondral bone and
limb bud cartilage formation. TGF-B inhibits some of the effects of
BMP-2B in chondrogenesis and may modulate the effects of the BMP
family in v/vo41b.
There is little data in the literature on the regulation of osteoblast
cytokine secretion by TGF-B. Such a relationship between TGF-B and
cytokine secretion could have profound effects on not only

bone

remodeling itself, but on the development of the neighboring colonies

of bone marrow cells which could be stimulated by bone cell-derived
cytokines.

As this thesis presents the first data supporting a role for

TGF-B activation of osteoblast-cytokine secretion, it would be
advantageous to discuss briefly the major properties known about the
bone cell-derived cytokines studied in this work, as follows concerning
Interleukin-6 (IL-6), Interleukin-1 (IL-1), GM-CSF and M-CSF.

B.
INTERLEUKIN-1 Coley's toxins and LPS; Discovery of IL1; IL-1A and IL-1B are processed differently; IL-1B is studied in this thesis._
In the late 19th century, William B. Coley, a New York City
surgeon, observed that several patients of his with terminal cancer
of comparable stage and who contracted low-grade Gram negative
bacterial infection had less morbidity and metastatic disease than
similar patients free of infection. Reviewing experiments by
Germany's Pfeiffer

on 'Gram

negative' cell walls,

Coley

conjectured that there was some component of the causative
bacteria which enabled the patient's body to fight neoplastic disease.
Eventually, Coley isolated fractions of Gram negative bacterial
cell walls, eventually called 'Coley's toxins', which he used with
considerable success to treat several patients with bone and soft
tissue sarcomas46,202# gy World War I, however, use of Coley's
toxins fell into disfavor partly because the use of such toxins was
accompanied by undesirable side effects including extreme nausea,
confusion and a profound fever. It would not be known for fourty
years that the effects of Coley's endotoxins were due to a molecule
known as

lipopolysaccharide (LPS).

It would be sixty years

before it was known that Coley's toxins, or the LPS moiety of
endotoxin, had been inducing the body's production of a hormone
called Interleukin-1, the isolation of which has revolutionized
immunological science. In 1942, Menkin et al. characterized the
physiologic responses to the administration of endotoxins136.
After an intravenous dose of 25 mg/kg of endotoxin, animals

Figure II.vi. Dr. William B. Coley, Surgeon (1926), 1862-1936. In the late 19th
and early 20th centuries, Coley became the first investigator to use biologic
molecules in attempts to potentiate the immune reponse to cancer.
His
preperations of endotoxins were later determined to contain lipopolysaccharide
(LPS), one of the most potent inducers known of IL-1 synthesis and release, the
probable mediator of endotoxin immunopotentiation. Photograph courtesy of the
New York Academy of Medicine Library.

expressed a profound, acute fever often as high as 39.5 degrees
Celsius. Menkin termed the causative molecule pyrexin and
believed that fever was caused by endotoxin-induced pyrexin and
not by endotoxin itselfI36. In 1949, Beeson eventually isolated a
protein candidate in granulocytes for pyrexin, a protein he termed
'granulocyte pyrogen' or GP12.

There was much debate on

whether pyrexin and GP were actually pyrogenic or whether
endotoxin itself caused fever.

In 1970, however, Bodel was the

first to show that a 14-15,000 Dalton protein,

isolated from

endotoxin-stimulated granulocytes, could cause fever, a molecule
termed the Leukocyte Endogenous Mediator, or LEMl8.

By

1971, several laboratories, including Gery et al.67, Oppenheim et
al.151, and Calderon et al.27

began describing a soluble factor

produced by stimulated macrophages which increased thymocyte
DNA synthesis.

The activating entity was termed Lymphocyte

Activating Factor, or LAF, produced by macrophages exposed to
bacterial endotoxins (LPS) or lectins (PHA)l7. Using similarlyactivated macrophages, laboratories began describing a wide
variety of activities induced by a soluble factor(s).

Besides LEM

and LAF above, other workers described an inducer of acute phase
protein synthesis called Hepatocyte Activating Factor, or HAF, an
inducer of muscle wasting termed catabolin, an inducer of bone
resorption termed Osteoclast Activating Factor, a stimulator of
primitive hemopoetic cells called Hemopoeitin-1, and an inducer of
serum

proteins

known

Factor50,51,55,139,156#

as

Amyloid-A

Stimulating

However, with the initial purification of

LAF by Blyden and Handschumaker in 197418, it was found that

all of the above activites could be attributed to one, single
molecule51.

With the observation that the molecule was

macrophage-derived and could stimulate other white cells,
including T-cells, the molecule was eventually known as
Interleukin-1 (IL-1).

Additional characterizations of IL-1

determined that at least two related proteins exist with IL-1
activity, differing in isoelectric point (pi) and various tertiary
configurations- IL-1

a and IL-1 13 with pis of 7.0 and 5.0,

respectively1 lla.207.

Despite differences in homology and trans¬

species conservation, IL-1 a and IL-1- B are ligands for the same
receptor and have, in general, identical modes of action. The IL-1
a gene is located on chromosome 2 in the mouse and is remarkable
for the absence of any upstream enhancer sequences like TATA, or
CAAT63.

The 10206 base pair gene is transcribed into a 2.3

kilobase (kB) message, and translated into a 268-271 amino acid
precursor of 38

kDaHll)*141,

IL-1 B is also located on murine

chromosome 2, but has several TATA and CAAT enhancer
sequences just upstream of the Start point. The 7008 base pair gene
is

transcribed into a shorter 1.4-1.8 kB mRNA,

and translated

into a similar 33-38 kDa precursor of 266-269 amino

acids^3.

Both proteins must be cleaved in an as-of-yet undetermined process
to yield the mature 17-18 kDa polypetides16’50.

Neither protein

has an N-terminal hydrophobic secretory signal suggesting that ILls are released by a unique mechanism, possibly via cleavage by
species-specific membrane

proteins.

Kobayashi et al. have

presented the model whereby precursor IL-1 a is phosphorylated
and then associated with a calcium-dependent acidic phospholipid

on the membrane outer surface which releases mature IL-1 alllb.
In contrast, IL-1 B, which is released earlier and faster than IL-1
a, is thought to be bound without phosphorylation to a trans¬
membrane processing protein, which releases mature IL-l-B.
Recently, Bakouche et al. have presented data suggesting that
mature IL-1 is released via lysosomal vesicles8a>8b.
In 1982, Auron et al. eventually cloned a cDNA from activated
human macrophages, and both species of human IL-1 cDNAs were
cloned, sequenced and expressed by 19857.
Cell Sources of IL-1 In Vivo. Produced mostly by activated
macrophages, but also by T-cell classes, keratinocytes and osteoclasts.
By far, the largest source of Interleukin-1 is derived
from the phagocytic leukocytes: peritoneal and tissue macrophages
and blood monocytes, from which IL-1 was first purified in low
picomolar concentrations18.

Kupper et al. have shown that non-

stimulated keratinocytes are active secretors of IL-1 a, a finding
that

continues

to

have

immunodermatology116^1^.

great

implications

in

Muegge described IL-1 production

by killer T-cells in the late 1980’s and then found IL-1 in y/S Tcells as well.

Although mice make more IL-1 a than IL-1 B, IL-1

B is believed to be the more active isoform in macrophage biology
and is the IL-1 species studied in this thesis.
Activities of IL-1

Perhaps few other molecules in

biological research have been implicated in as many diverse
systems of physiology as Interleukin-1.

Summarized here will be

only those activities of the hormone which are most relevent to the
studies in this thesis, although the interested reader may be referred
to several excellent reviews 50,55.

i. Stimulation of T- and

B-cells. Induces IL-2

production; IL-1 may activate B-cells.

Larrson et al. first presented data in 1980
demonstrating that T-cell production of T-cell derived growth
factor (TCGF), now known as Interleukin-2 (IL-2), was supported
by a 20 kDa molecule derived from macrophages, later identified
as Interleukin-1123.

The observations were some of the first to

characterize the crucial T-cell/macrophage axis, perhaps the most
important arm of the early activation of the immune system.

IL-1

secretion and consequent IL-2 production can greatly increase Tcell clonal expansion and proliferation.

Furthermore, IL-1 can

synergize with IL-2 to enhance IL-2 responsiveness 132.
B-cells can be stimulated at precursor stages and after
exposure to antigen by T-cell derived cytokines like B-cell Growth
Factor (BCGF) and Interferon-gamma (IFN-y) and possibly IL2125.

Several laboratories have shown that B-cells in quiescence

can be brought to Gi, driven into mitosis1**!, and eventual
immunoglobulin secretion by Interleukin-1 and the T-cell-derived
cytokines !25.
ii. Stimulation of acute phase cells, acute phase proteins
and features of inflammation.
IL-1 is a potent chemotactin and degranulator
for neutrophils, eosinophils and other macrophages, implicating the
hormone as an amplifier and director of early stages of
inflammatory events.

IL-1, formerly studied as Hepatocyte

Stimulatory Factor (HSF), can induce a large spectrum of acute
phase proteins from liver cells in vitro (see below)

156,161

IL-1

also induces arachidonic acid metabolism, with the consequent

production of leukotrienes and prostaglandins50.

Glucocorticoid

therapy for inflammation may down regulate prostaglandin
synthesis in at least two ways- inhibition of cylooxygenases, and by
inhibiting transcription of the IL-1 gene via a Glucocorticoid
Binding Element (GBE) 50.
iii. Induction of M-CSF. GM-CSF. and IL-6 synthesis.
Kaushanksy et al.104 and Zucali et al.214
have presented data on dermal fibroblasts showing that IL-1 can
induce the production of Granulocyte-Monocyte CSF (GM-CSF)
and Granulocyte-CSF (G-CSF). IL-1 did not, however, induce the
production of Macrophage-CSF (M-CSF) in the Kaushansky
group's studies.

Stanley et al.184, and Bartelmez et al.10, studied

Hemopoetin-1 (H-l), a growth factor isolated in 1985 from human
bladder carcinoma cells and later determined to be IL-1 itself.
Data indicated that although H-l alone had no effect on colony
stimulation in vitro, H-l synergized with other colony stimulating
factors, like M-CSF (CSF-1) and Interleukin-3 (IL-3), to induce
hematopoesis at earlier stages than either M-CSF or IL-3 alone.
Several workers have also described the induction of
Interleukin-6 (IL-6) production in fibroblasts by IL-1177. Released
IL-6, as reviewed above, may stimulate both hematopoesis as well
as the synthesis of C-reactive and acute phase proteins65,161

IL-6

may mediate some IL-1 effects. Such evidence implicates IL-1 not
only in early stages

(0-12 hours) of immunoreactivity against

foreign invasion, but the later stages by inducing potentially
immunoreactive cell precursors towards maturity.

iv. Interactions with complement.

C5a induces macrophage IL-

1 synthesis; IL-1 can activate C3 and Factor B.

Macrophages do not constitutively secrete IL1, but will produce large amounts when exposed to complement
products

such as C5al42b. In turn, IL-1 stimulates hepatocyte

production of Complement factors

3

and

B156,161.

As more

species of animal systems were described for IL-1 activities, it
became clear that the molecule had an extraordinary degree of
conserved homology, even over presumably large evolutionary
divisions. Human IL-1, for example, shares 95 % homology with
primate IL-1 (chimpanzee) and 90% homology with the horseshoe
crab (Figure ILxii).

Starfish Factor B, derived from coelemic

phagocytes, is now known as Interleukin-1H.

It was the presence

of active IL-1 in echinoderms that suggested IL-1 was extremely
old, since horseshoe crabs are believed to have changed little since
the late Jurassic period (160-140 million years ago).

There is

evidence that IL-1 may induce the alternate pathway of the
complement cascade and is induced by complement products like
C5a (see figure

Il.xii)142.

Such observations suggest that IL-1 may

have operated in simple immune systems, like those of the
echinoderms- devoid of antibody production but dependent upon
coelemic phagocytes and phagocyte-derived IL-1 to induce
inflammatory changes.

v. Pvrogenesis and prostaglandin E? production .

IL-1 8
induces fever by increasing hypothalamic PGE2 mediated perhaps by CRF.

IL-1 was originally studied as the LEM, or
Leukocyte Endogenous Mediator, or simply, the Endogenous
Pyrogen (EP), as the inducer of acute rises of body core
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temperature to levels of fever.

Although there exist other

cytokine pyrogens, like IL-6, Tumor Necrosis Factor and
Interferon a, IL-1 is at least 50 times as potent, acting as a pyrogen
in doses of 2 ng/kg55.

IL-1, and the other pyrogenic cytokines,

most likely induce fever by inducing the synthesis of prostaglandin

Figure ILvii. Left, the horseshoe crab, Limulus polyphemus, one of the oldest
animal species on earth. The crab's coelom is patrolled by host phagocytes which
are active producers of an Interleukin-1 species that is 95% homologous to human
IL-1, and which may be involved in a complement-dependent type of primitive
immune system. Right. IL-1 activation of the alternate complement cascade,
effective in generating Membrane Attack Complexes (MACs) in the absence of
antibody. IL-1 induces C3 and B synthesis in hepatocytes thus fueling the
cascade. Production of C3a and C5a may contribute to IL-1 mediated
inflammation and hypersentitivity reactions, (ap) = anaphylatoxins.
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E2 (PGE2).
levels

of

Endotoxin, or LPS exposure,
PGE2

hypothalamus24’174.

in the brain,

leads to increased

spinal fluid and

in the

As shown below in figure Il.xiii., released

PGE2 in the brain may trigger heat controlling centers in the pre¬
optic nucleus of the anterior hypothalamus which, in turn,
transmits thermogenic information to the periphery causing the

CORTISOL

DIAPHORESIS
SHIVERING
VASODILATION

Figure II. viii. IL-1 pyrogenesis and the IL-1 pituitary-adrenal axis. Endotoxininduced release of IL-1 leads to increased hypothalamic PGE2, resetting
hypothalamic autonomic outflow to raise body temperature. The PGE2 also
functions to release CRF from the hypothalamus which induces the release of
ACTH from the anterior pituitary. Cortisol, produced in the adrenal cortex after
ACTH stimulation, functions to directly suppress macrophage production of IL1, thus acting as the negative feedback arm of the axis.

body temperature to rise.
hypothalamus as well.

IL-1 may have direct effects on the
Although it is believe IL-1

resets

hypothalamic temperature regulation via prostaglandin synthesis,
Busbridge et al. have presented evidence suggesting at least some of
IL-l's pyrogenicity may be mediated by Corticotropin Releasing
Factor (CRF)24.

It was first noted in 1986 by Besedovsky et al.14

and Uehara et al.i93 that IL-1 participated in a hypothalamic
pituitary-adrenal axis by inducing hypothalamic release of CRF and
consequent adrenocorticotropic hormone (ACTH) from the
anterior pituitary.

Glucocorticoids released from stimulated

adrenal glands then inhibited in a feedback mechanism ACTH
release, CRF release and IL-1 release from leukocytes.

Clinicians

had used endotoxin itself as a common clinical test for anterior
pituitary-adrenal axis function24.

However, Busbridge et al.

found that IL-1 13-induced fever could be blocked by both anti-CRF
antibody and CRF receptor antagonists.
could not be similarly blocked.

IL-1 a-induced fever

IL-1 6 mRNA is expressed in the

hypothalamus but IL-1 a mRNA is not24.

Further studies,

especially in vivo studies of brain tissue, will be needed to clarify
these observations.

IL-1-induced fever is probably an important

mechanism of heightening the immune system in the bodys general
response towards foreign invasion, although the exact function of
hyperthermia in pathologic states is not yot clear.
vi. Interleukin-1 and Bone. Osteoblasts express receptors for
IL-1 while osteoclasts do not. IL-1-induced effects on osteoclasts may be
regulated via osteoblast-derived factors.
As early as the 1880s, clinical descriptions of
multiple myeloma have included reports of abnormal bone

resorption and

associated sequellae:

hypercalcemia, profound

osteoporosis, bone fractures and bone pain. Bone pathology is a
hallmark of multiple myeloma and is one of the most debilitating
aspects of the disease.

Myeloma cells can elicit hormones as

Osteoclast Activating Factor (OAFs) which activate osteoclasts to
resorb bone unchecked by normal controls94.

OAFs include

Tumor Necrosis Factor 6 and IL-1B. Some workers suggest IL-1
is less important in vivo as an OAF83 but IL-1 in vitro is 10 times
more potent than TNF for decreasing proteoglycan synthesis in
cartilage171.
Osteoblasts express receptors for IL-1 while osteoclasts do
not167c.

IL-1, however, has been found to increase osteoclast

development, osteoclast precursor number69,!87? and osteoclast
collagenase production78. IL-1 stimulates osteoblast production of
Macrophage-Colony Stimulating Factor which may then act, in a
paracrine

fashion,

to

induce

the

development

of

osteoclasts7713’128b,206# Paracrine activity by osteoblasts may be
important in mediating the other effects of IL-1 on osteoclast
development outlined above.
IL-1 may induce bone resorption by increasing local
prostaglandin E (PGE) production110’172 but other workers
suggest a direct resorptive effect147. PGE as a single agent is a
potent inducer of matrix resorption in vivo110. IL-1 induced bone
resorption is decreased by TGF-B157. Such findings suggest that
IL-1 may be an important mediator in the regulation of bone
remodeling.

The IL-1 receptor and IL-1 signal transduction
The determination and analysis of the IL-1 receptor was
greatly facilitated by the cloning and expression of purified IL-1
from isolated cDNAs in 198650’56’207. Early experiments reported
receptor protein candidates with several molecular weights, but after
the isolation of receptor cDNAs, it was determined that the IL-1
receptor was a single glycoprotein of 80 kDa15.

The complete

amino acid sequence has been determined including a membrane
spanning domain of 21 amino acids2’2!. Putative protein kinase C
acceptor

(Gly-x-Gly-Ser-x-Ser)90,92

also been identified29’77.

and cAMP binding sites have

Despite this initial data, however, it is still

unclear how the IL-1 receptor transduces ligand binding into
intracellular signalling2’^, 138,150#
Many hormone receptors transduce extracellular stimulation by
utilizing second messenger systems to activate specific intracellular
kinases: cyclic nucleotide hydrolysis for activation of cGMP/cAMPdependent kinases or phospholipid hydrolysis for calcium/diacyl
glycerol-dependent

kinases14’92’153.

There is much debate

concerning which second messenger system predominates in the IL1-stimulated cell.

Many transcription factors and co-factors are

activated by IL-1 so the second messenger systems which mediate the
IL-1 response may be complex.
Mizel et al. provide evidence of protein kinase A activation by
cAMP hydrolysis in IL-1 stimulated T-cells150. In contrast, other
workers report that IL-1 does not raise T-cell cAMP levels and has
no effect on intracellular levels of diacylglycerol, calcium, or
phosphoglycerides^BSJSO. O'Neill et al. have found that a

stimulatory G protein activates a novel serine kinase in IL-1-exposed
T-cells.

Rosoff et al.168 have presented data concerning Jurkatt T-

cells that suggest IL-1 may transduce its signal not via classical PI
hydrolysis,

but rather through

a novel hydrolysis of membrane-

bound phosphotidylcholines (PCs).

The Rosoff group showed that

Figure Il.ix. Theories of signal transduction by the IL-1 receptor in T-cells. As
suggested by Rosoff et al.168, T-cell co-stimulation by LL-1 and anitgen may be
achieved through the production of differing species of diacylglycerols (DAGs)
and the synergistic activation of trasncription factors (TFs). As illustrated above,
antigen stimulation of the T-cell receptor induces classic PI turnover with the
production of free intracellular calcium (not shown) and diacylglycerol species 2
(DAG-2). IL-1 induces hydrolysis of rapidly-shuttled phosphatidylcholine (PC)
for the production of calcium (not shown) and diacylglycerol species 1 (DAG-1).

DAG-1 and -2 activate species-specific protein kinases C (PKC-1 and -2),
respectively. PKC-1 and -2 synergize to activate transcription factors (TFs) or
enhancers. IL-1 may have hydrolyzing capabilities and may hydrolyze PC
directly (a). Altemativately, IL-1 may hydrolyze PC via a membrane-bound
hydrolase (b) or through a classic IL-1R and an associated phospholipase (c).
IP3=inositol triphosphate, MHC=multiple histocompatability, APC=antigen
presenting cell, PLC=phospholipas C, PLX=putative phospholipase, PIP2=
phosphotidylinositol diphosphate, PCv=vacuolar PC, PCm=membrane-bound
PC, TFi/TFa=inactive/active TF.

PC hydrolysis after IL-1 stimulation

produces diacylglycerol

(DAGs) species with different fatty acid side chains than DAGs
produced

by

PI

hydrolysis

after

antigen

stimulation.

Furthermore, IL-1 induces PC hydrolysis on outer cell membranes
and on many internal membranes as well, liberating DAG
molecules throughout the Jurkatt cell cytoplasm.

Jurkatt T-cells,

however, as assayed by Rosoff et al.168, have no IL-1 receptors,
or at least less than 200 receptors per cell. Rosoff suggested that
IL-1 may have dual effects on a cell.
for a low number, high-affinity

First, IL-1 may be a ligand

IL-1 receptor.

Secondly, IL-1

may have intrinsic PC-hydrolyzing ability and may directly initiate
outer membrane-bound PC hydrolysis without a receptor
intermediate.
Signal transduction by IL-1 is still, therefore, unclear, but an
important model arises with particular relevance to this thesis as
presented in figure II. ix. :

IL-1 induces PC hydrolysis, via

unknown pathways, to increase DAG production throughout the
cell. Concomitantly, a secondary signal, antigen, lectin or OKT3
antibody against the T-cell receptor (TCR), initiates TCR signal
transduction via classical PI hydrolysis with the production of other
DAG species and free intracellular calcium.

The two differing

species of DAGs may act on different protein kinases C or A and

synergize for transcription factor or co-factor cativity.
utilization

The

of two seperate signalling pathways which converge

upon and synergistically activate common trans- or cis- gene
activators may be an important mechanism of cellular activation
with importance to the discussion of data presented in this work.

C. INTERLEUKIN 6 Discovery of the roles of IL-6 in
B-cell maturation; IL-6 production; In vivo sources of the hormone._

The immune system relies heavily upon B-cells to produce
antibody against specific antigens foreign to the host.

The only

antibody producing B-cells, however, are those B-cells which are
fully differentiated and appropriately stimulated with antigen.
These two conditions may be achieved by the presence of T-cells and
antigen-presenting macrophages.

By 1982, it was clear that certain

soluble growth factors could substitute for the apparent function of
T-cells and macrophages in the process of B-cell stimulation!76’21 L
In 1986, three of the putative growth factors were isolated and
cloned 109. As illustrated in figure II. vi below, the first factor was
Interleukin-4 (IL-4), originally called B-Cell Growth Factor-1
(BCGF-1) or B-Cell Stimulatory Factor 1 (BSF-1) because the
molecule functioned to activate early B-cell progenitors exposed to
antigen. The second factor was Interleukin-5 (IL-5), then known as
BCGF-2, which functioned to induce growth in activated B-cells.
The third factor functioned to induce the differentiation of growing,
activated B-cells into antibody-producing B-cells. This third factor,
originally called B-cell Differentiation Factor (BCDF) or B-cell

Stimulatory Factor 2 (BSF-2), is now known as Interleukin-6 (IL-6).
Like Tumor Necrosis Factor (TNF) and Interleukin-1 (IL-1), IL-6

Figure II.x. The B-cell growth factors. Pre-B cells are activated (act-B) by IL-4
and express receptors for IL-5, which in turn, stimulates activated cells to assume a
'primed' state (B'). Only then can IL-6 induce such cells to synthesize and secrete
antibody. IL-7 may funtion to upregulate pre-B cell growth and differentiation.

was also studied as the major inducer of acute phase protein
synthesis, and in this regard IL-6 vvas also known as Hepatocyte
Stimulatory Factor (HSF)31’165

Like many growth factors, IL-6 is

a small protein of 184 amino acids.

Mouse and human IL-6 DNA is

60% homolgous for the gene coding region, but 90% homologous
over 300 base pairs at the extreme 5' end of the gene suggesting an
important regulatory site.

Additionally, the 5'-flanking sequences

of each exon in the gene is similar to previously identified
transcription enhancer elements like the serum reponse elements
(SRE) of c-fos, the Early Growth Response genes, or the
glucocorticoid receptor binding element (GRE)109,188 Although
mouse and human IL-6 protein are only 42% homologous, the two
species are 100% homologous in the position of the four cysteine
residues in the molecule. Such cysteine homology is also shared by

a hematopoietic growth factor called G-CSF suggesting that cysteine
residues may be important to IL-6 and G-CSF activity.
IL-6 is produced by T- and B-cells, monocytes and macrophages,
fibroblasts, keratinocytes, endothelial cells, some tumor cells, and
osteoblasts60’76’84. IL-1 is a potent inducer of IL-6 production in
these cells, an effect inhibited by TGF-BI44.
Roles of IL-6 in the immune system. T-cell activation; Mediation
of IL-18; Lennert's disease.

Unlike resting B-cells, resting T-cells express surface
receptors for IL-6.

Once stimulated with IL-6, T-cells express

receptors for Interleukin-2 (IL-2), the T-cell growth factor109.

IL-

6 also stimulates the production of serine esterases in T-cells,

an

enzyme crucial to T-cell cytotoxicity109. IL-6 was identified as the
soluble factor in addition to IL-2 that was necessary for the induction
and growth of cytotoxic T-cells (CTLs)39.

In vivo,

T-cell

stimulation by IL-6 may most likely be achieved by constitutive IL-6
production by macrophages. IL-6 may mediate the effects of IL-l-B,
an effect ablated by TGF-B51’144. The importance of this cellular
relationship is illustrated clinically in Lennert's T-cell lymphoma, a
non-Hodkin's lymphoma. In Lennert's disease, massive infiltration
of lymphoid

tissue

by

macrophage-derived

histiocytes

is

accompanied by the growth of T-cell lines which are dependent upon
the presence of the infiltrating macrophages109.

IL-6 in vitro may

substitute for macrophages in supporting the growth of Lennertine
T-cells because antibody to IL-6 completely abrogates the growth
effects of the macrophages upon the T-cells175.

Roles of IL-6 in hematopoiesis. Blast cell activation with
IL-3 for granulocyte-monocyte lines; Role in megakaryocytopoiesis; Activity in
multiple myeloma; Uses of IL-6 in transplantation medicine.
IL-6 has a potent ability to induce hematopoietic
stem cells from the quiescence of Go into the active growth of Gi.
A second growth factor, Interleukin-3, can stimulate such activated
blast cells to grow and differentiate along various lineages into blast
cell colonies.

Although granulocyte-monocyte lines typically

develop from stimulated blast cells, Koike et al. have shown that IL6 also

upregulates megakaryocytopoiesis112.

Murray et al.

demonstrated that IL-6 mRNA is clearly expressed in 4-day old
murine blastocysts suggesting that IL-6 may be important in
embryonic

stem cell development and the first stages of

hematopoiesis 143.
The synergistic interaction of IL-6 with IL-3

for the

establishment and growth of blast cell colonies in vivo may also be
important in clinical science; IL-6 and IL-3 have already been used
to super-induce the formation of bone marrow cultures in
preparation for transplantation.

In fact, Okana et al. has observed

that transplanted marrow cells which were pre-cultured with IL-6
before exposure to IL-3 had a survival rate of 90% while noncultured marrows had only a 20% survival rate149b.
IL-6 is a strong stimulator of growth in myeloma cells and
plasmacytoma cells, and anti-IL-6 abrogates such growth. Myeloma
cells also produce IL-6

and are therefore likely to maintain cell

growth via this autocrine mechanism109.

Roles of IL-6 and the endocrine system. The pituitaryadrenal axis; Suppressionof IL-6 with dexamethasone.

As illustrated in figure II. vii below, IL-6 induces the
release of corticotropin releasing hormone (CRH), which functions
to induce the release of adrenocorticotropic hormone (ACTH)146.
ACTH stimulates adrenal cortex cells to produce glucocorticoids,
which, in turn, function to inhibit IL-6 production.

Both IL-6 and

glucocorticoids function to induce acute phase proteins^ 1,32.
Glucocorticoid suppression of IL-6 production suggests an important
feedback mechanism in the regulation of the molecular response to
stress.

Figure II.xi. The pituitary-adrenal IL-6 axis. IL-6 induces the release of
corticotropin releasing hormone (CRH) from the hypothalamus. CRH, in turn,
induces adrenocorticotropic hormone (ACTH) release from the anterior pituitary.
Finally, adrenal cortisol, produced secondary to ACTH stimulation, functions to
both down-regulate hypothalamic IL-6 receptors as well as decrease systemic IL-6
production itself.

IL-6 in bone. Produced by osteoblasts in response to various
stimuli; Implicated in osteoclast formation; Role in osteobiology unclear.

Normal primary osteoblasts do not constitutively express IL-6
mRNA but will transcribe IL-6 genes and produce and secrete IL-6
in

response

to

lipopolysaccharide

numerous

stimuli

(LPS)85,87?

parathyroid hormone (PTH)84.

including

exposure

to

Interleukin-1 (IL-1)17L172, and
The role of IL-6 in normal or

pathologic bone and calcium metabolism, however, is not clear.
There have been reports that IL-6 can stimulate proliferation
and differentiation of osteoclast precursors117, potentiate IL-1mediated bone resorption117 and inhibit osteoclast activity64.
Glucocorticoids may inhibit IL-1-induced bone resorption by
decreasing IL-6 mRNA production and hormone secretion94.
Although these studies implicate IL-6 in a feedback mechanism
between osteoblasts and osteoclasts to regulate local ratios of bone
formation to bone resorption, data has not been widely confirmed.
IL-6 may be produced by osteoblasts in fracture sites. This IL-6 may
chemoattract and activate local acute and chronic phase cells of
inflammation and repair.
suggests

LPS-,

Evidence is presented is this thesis that

IL-1- or PTH-induced IL-6 production by

osteoblasts can be greatly accelerated and increased by cell priming
with Transforming Growth Factor-Beta.

THE COLONY STIMULATING FACTORS (CSFs)

Every second of human life consumes 500,000 granulocytes, a
number of cells which must consistently be replaced to avoid a
systemic decrease in granulocyte number and the life-threatening
condition of granulocytopenia.

Granulocytes, and all other cell

types normally present in the blood, arise from progenitors in the
bone marrow, as the final cellular stage of long lineages in
hematopoetic development.

The reverse pyramid of blood cell

formation is thought to be initiated by the growth of one single
stem cell, a pluripotent progenitor of all cell types.

During times

of blood cell need such as infection or anemia, the marrow can
produce up to ten times the baseline number of cells in as little as
48 hours suggesting that the development of stem cells into fully
differentiated cell types can be regulated.

In the 1960's,

the

development of semi-solid media enabled researchers to establish
cell culture systems for cells normally present only in bone
marrow;

cell progenitors which eventually differentiate into

mature colonies

of granulocytes, monocytes/macrophages,

megakaryoctyes, etc.

Using semi-solid media systems, it was

found that cell types could not sustain cell division for more than
48 hours in media alone. Rather, cell colonies could be initiated
and sustained when certain fractions of marrow serum were
included in culture.

Specfic regulatory molecules were isolated

from serum, and, since the molecules were identified by their
ability to induce the growth of cell colonies, such molecules were
referred to as Colony Stimulating Factors, or CSFs137b. Because
the CSFs were present in extremely small amounts in vivo , it

required many cycles of high-performance liquid chromatography
to concentrate the molecules to analytical levels, in some cases, onemillion times the concentration in vivo. Eventually, four distinct
CSFs were isolated and cloned from murine and human bone
marrow.

As the properties of the CSFs began to be elucidated it

was found that the molecules affected not only disparate branches
of the hematopoetic family tree, but affected cells at certain stages
of differentiation (figure Il.xii). Therefore, one CSF affected the
early, common progenitor for both granulocytes and monocytes,
and is therefore called Granulocyte-Macrophage CSF, or GM-CSF.
A second induced the growth of only those cells which developed
into macrophages (Macrophage-CSF, or M-CSF) and a third,
Granulocyte-CSF (G-CSF), was

an inducer of relatively well-

differentiated pre-granulocyte colonies.

The fourth, Interleukin-3,

was by the far the earliest effector of cellular growth, inducing the
proliferation of almost all cell types, including stem cells
themselves.

Since the CSFs are important in normal cellular

growth, the hormones have also been implicated in disorders of
excessive white blood cell growth (leukemia, thrombocythaemia),
and of reduced white blood cell growth (granuloctyopenia,
thrombocytopenia).

Successful clinical trials in the treatment of

neutropenia (acquired and intrinsic) have only heightened the
interest in studying the CSFs as important hormones in disease and
medical treatments.
Despite the importance of the CSFs in blood cell formation,
they

possess other activities in vivo ,

and are made by non¬

marrow resident cell types like fibroblasts43, keratinocytesll6a, and

Osteoclast
Macrophage

Figure Il.xii. Hematopoetic growth factors and cell lineages. An unknown
factor induces stem cell proliferation and early maturation. It is not known how
early ultimate cell fates are determined. Blood Forming Units-Erythroid (BFUE), Colony Forming Units-Megakaryocyte (CFU-Meg) and -Eosinophil (CFUEo) are formed early. CFUs-Granulocyte/Monocyte (CFU-GM) form an
immense pool of precursors, from which are derived all neutrophils,
macrophages, osteoclasts, and other tissue phagocytes.

osteoblasts85. Osteoblasts make large amounts of GM-CSF and MCSF in response to various stimuli like lipopolysaccharide (LPS),
Interleukin-1, and parathyroid hormone60’86’87’204.
D. GRANULOCYTE-MACROPHAGE CSF (GM-CSFh GMCSF is a monomeric protein whose cDNA was eventually isolated

and cloned in 1985 by Wong and coworkers209. Four cysteine
residues are required for the two disulfide intramolecular bonding
necessary for activity.

Precursor proteins are processed only at

the amino end to yield a 23-24,000 Dalton (Da) mature molecule,
capped by an alanine-proline dimer at the amino terminus.

The

size of the GM-CSF species is determined by the number of the
two asparagine sites in the protein which are glycosylated52.
Double-site glycosylation will yield molecules which are 50%
carbohydrate by weight52^. The sugar moieties have no apparent
function in vitro and, in fact, decrease the growth promoting
activities of the molecule.
GM-CSF & Hematopoesis. Stimulation of multiple
lineages at different points of maturity.

GM-CSF affects granulocyte and monocyte
formation by stimulating certain progenitor cells at various time
points in hematopoesis, from very early to very late. As illustrated
above in figure Il.xii, GM-CSF has been shown to stimulate some
of the first daughters of stem cell division. The stimulated cells
form colonies, or colony forming units (CFUs), from which are
derived all non-lymphoid blood cells; granulocytes, erthyrocytes,
monocytes, and megakaryocytes and thus are called CFU-GEMMs.
GM-CSF stimulation of CFU-GEMMs induces the production of
more differentiated colonies of cells, committed to four other
lineages. One, an erythroid burst forming unit (BFU-E) is further
stimulated by GM-CSF, IL-3 or erythropoetin to form erythroid
CFUs and then reticulocytes. A second lineage, a megakaryocytic
CFU (CFU-MEG) is first stimulated by IL-3 and GM-CSF and then
by erythropoetin to form mature megakaryocytes. A third lineage,

CFU-Eo, is stimulated by IL-3 to form basophils and by both IL-3
and GM-CSF to form eosinophils.
into

a CFU for granulocytes

Stimulation

The fourth lineage develops
and monocytes,

CFU-GM.

of CFU-GMs by IL-3 and GM-CSF induces the

production of monocytes.

GM-CSF stimulation of monocytes, in

turn, induces maturation into tissue and blood macrophages.
Stimulation of CFU-GMs by IL-3, GM-CSF, and Granulocyte-CSF
(G-CSF) produces mature neutrophils.
Sources of GM-CSF in vivo. Lack of evidence for
constitutive release in marrow; Production og GM-CSF by activated T-cells,
macrophages, and osteoblasts.
The requirement that the marrow produce blood
cells at different rates throughout an individual's life points to the
regulation required for the production of GM-CSF and the other
hematopoietic hormones.

Furthermore,

normal cells thus far

examined constitutively express minute quantities of GM-CSF
messenger RNA, suggesting that the hormone is produced only
when needed.

Isolatable quantities of hormone are obtained from

cells, such as murine alveolar cells, only after stimulation, i.e. with
endotoxins23.

T-cells209, stromal cells21!, and osteoblasts86 will

all produce quantities of GM-CSF after appropriate stimulation
with endotoxin or tumor necrosis factor (TNF).
observations support the hypothesis that

Such

the rapid induction of

acute phase cell growth during times of infection is achieved after
the release of GM-, G-, and M-CSFs from activated cell types.
Although one may implicate GM-CSF in the maintainence of
normal, steady-state hematopoesis, no definitive data yet exist to
show that the hormone is constitutively produced in the bone

marrow.

Because of GM-CSF's low concentration in vivo, it may

be difficult to detect constitutive secretion of the hormone by
marrow stromal cells into microenvironments to induce CFU
activity.
GM-CSF and osteoblasts. Produced by stimulated
osteoblasts; Hypersecretion in the transgenic TAX mouse; Growth factor in
osteosarcoma.
In 1988, Horowitz et al.86 showed that osteoblasts
secreted large quantites of GM-CSF when appropriately stimulated
with

1-10 nM parathyroid hormone or

lipopolysaccharide (LPS),

the mitogenic component of Gram

negative bacterial cell wall endotoxin.
suggested that

1-10 pg/ml of

In situ hybridization data

no messenger RNA for GM-CSF is consitutively

expressed in osteoblasts but message levels are greatly increased
after a 24 hour hour exposure to LPS86.

GM-CSF is not

mitogenic for osteoblasts but may positively affect the development
of osteoclasts128b’l67c. GM-CSF does not affect levels of other
bone-regulating hormones like PTH, calcitonin, or 1,25 (OH)2vitamin D387.

A new approach to the study of the hormone in

bone has been established using a mouse strain transgenic for the
transactivating (TAX) gene from the Human T-cell Leukemia
Virus -1 (HTLV-l)l69.

The transgenic animals were originally

designed to study the effects of the TAX gene on immune function
but were observed to have striking bone abnormalities, such as
evidence of greatly increased rates of bone turnover and 10-fold
increases in osteoclast number169. The TAX gene, by definition,
activates other genes in a trans

fashion, three of which are

Lymphotoxin, Interleukin-2 (T-cell Growth Factor) and GM-CSF.

Lymphotoxin, or Tumor Necrosis Factor-6, was previously
identified to be an activator of osteoclasts70 and was thought to be
at least one of the Osteoclast Activating Factors (OAFs)l71. The
production of such OAFs by the TAX gene was especially
intriguing since many patients who succumbed to T-cell leukemia
were not victims of the leukemic T-cells per se, but were victims
of flagrant hypercalcemia consequent to increased bone resorption.
Such observations have fueled interest in the roles of GM-CSF not
only in HTLV-l-induced bone resorption but in normal,
osteoporotic, and Pagetic bone resorption as well.

Evans et al.

reported that recombinant human GM-CSF stimulated osteoblast
proliferation, but inhibited osteoblast alkaline phosphatase activity
and 1, 25 (OH)2 vitamin D3-induced osteocalcin synthesis59.
Additionally, observations that GM-CSF is a growth factor for
osteosarcoma and acute and chronic myeloid leukemic cells has
implicated the hormone in neoplastic processes of liquid and
mineralized tissues as

well43’194.

Some reports have implicated

GM-CSF and other colony stimulating factors as inducers of
cartilage degradation by chondrocytes98.
GM-CSF and clinical applications. Treatment of
intrinsic and acquired leukopenias; Limited, yet promising results;
GM-CSF functions to maintain the biological activity of those
cells induced by the hormone. That is, GM-CSF not only induces
granulocytopoesis, it prolongs and enhances neutrophil and
eosinophil phagocytosis, chemotaxis and antibody-dependent
cytolysisl37a, and enhances macrophage syntheses of
prostaglandin E and plasminogen-activators43.

Donahue et al.

showed that continuous infusion of human GM-CSF into Macaca

48

fasicularis and mulatta monkeys induced a five-fold increase in
white cell counts within 36 hours without toxic effects53a. Later
experiments showed that GM-CSF infusion could also hasten the
recovery from marrow transplantation-induced
pancytopenia53b,170.

Laboratory successes prompted the use of

GM-CSF in clinical trials for patients with myelodysplastic
syndromesI95, aplastc anemia26’40, and the leukopenia of the
acquired immunodeficiency syndrome (AIDS)74’75.

In one study,

continuous intravenous infusion GM-CSF daily for two weeks in
patients with the myelodysplastic syndrome increased granulocyte
counts 5- to 373-foldl95.

Monocytes, eosinophils, and

lymphocytes also increased.

Dramatic increases in circulating

neutrophils, eosinophils, and monocytes in AIDS patients after GMCSF treatment fell to background 1-2 days after treatment was
stopped75.

Such clinical successes point to both the enourmous

potential of GM-CSF in medical treatments of hematologic disease,
as well as the hormone's short course of action.

E. MACROPHAGE-CSF (M-CSF). Exists as two different forms in
vivo; M-CSF induces the development of monocyte lines into macrophages. The
M-CSF receptor is encoded by c-fms.

M-CSF was the first hematopoetic growth factor identified by
analysis of spleen cell colony proliferation and was originially called,
therefore, Colony Stimulating Factor 1 (CSF-l)137b’l92.

cDNAs

for M-CSF were obtained only after the native amino acid sequence
of the protein was used to predict the nucleotide sequences of
disparate regions of M-CSF mRNA105.

Synthetically produced

oligonucleotides were then used to identify and eventually isolate a

complete cDNA for the M-CSF gene.

Various cell lines transcribe

the M-CSF gene into two species of mRNAs, a 1.8 kilobase message
and a 4.0 kilobase message. The 4.0 kB mRNA is produced after a
894 base insertion into the 1.8 kB mRNA105’210. As shown

1.8 kb
active
M-CSF
cDNA

*

4.0 kb

1

85 kDa

mRNA

Figure Il.xiii. M-CSF processing. Two forms of active dimeric M-CSF exist, a 45
and a 85 kDa proteins, both derived from a 1.8 and a 4.0 kb mRNA splice product,
from the same DNA transcript, respectively. The smaller mRNA differs from the
larger in that codons for 298 amino acids are inserted between residues 181 and 182
of the smaller species. There is some evidence that this may occur, in part, posttranscriptionally.

above in figure Il.xiii, the M-CSF mRNAs are post-translationally
processed into two different species of M-CSF hormone; the 1.8 kb
mRNA yields a 18-26 kDa protein and the 4.0 kb mRNA codes for a
35-45 kDa molecule2^.

The two proteins are then N-glycosylated

to attain molecular weights of 45 kDa, and 85 kDa, respectively.
The two proteins then form dimers with one other molecule of the
same weight species to yield an active M-CSF hematopoetin. Thus,
two different forms of the hormone exist in vivo ;

a dimer

consisting of two 45 kDa glycoproteins and another consisting of two
85 kDa glycoproteins 137a,
As shown in figure Il.xii, M-CSF induces promonocytes and
monocytes to differentiate into macrophages. In this respect, M-CSF
is unlike GM-CSF in that M-CSF affects cell types at relatively late

stages of maturation.

M-CSF also increases

cytotoxicity and appears to

macrophage

increase monocyte/macrophage

longevity43. M-CSF modulates hematopoiesis further by inducing
production of interferon-gamma and Tumor Necrosis Factor-alpha
from monocytes200.
M-CSF is unlike the three other CSFs in that there are 10-50
times the number of receptors for M-CSF on a given cell than there
are for GM-CSF, IL-3, or G-CSF25,137b,205,209.

The observation

that the M-CSF receptor, a 165 kDa glycoprotein, is identical to the
product coded by the proto-oncogene c-fms may implicate abnormal
transduction of signal by M-CSF receptors in neoplastic

growth173.

M-CSF and bone. M-CSF enhances osteoclast
proliferation; Op/op mice have osteopetrosis and are homozygous for a defective MCSF gene; Osteopetrosis resolves with M-CSF therapy.
M-CSF enhances the development of osteoclast
precursors7715’ 128b,206,212. The finding that osteoblasts produce MCSF in response to PTH and PTHrP suggests further that osteoblasts
may regulate osteoclast activity via paracrine hormone
production203.
Wiktor-Jedrzejczak and coworkers have shown that M-CSF
may have particular importance in bone cell biology, as illustrated
by the researcher's study of the bone disease, osteopetrosis.
Osteopetrosis is a disorder of bone remodeling consequent to a
profound deficiency of osteoclasts, the bone resorbing cell.
Children bom with the disease have extremely brittle bones which
are resistant to normal bone growth. Osteopetrotic children can be
effectively cured, however, by a successful transplant of bone
marrow. Normal osteoclasts eventually grow out from monocytic
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lines in the marrow and repopulate bone matrices throughout the
body (figure ILxii).

To study the disease process further, a mouse

strain was developed which was homozygous recessive for
osteopetrosis, the so-called op/op mouse206.

Op/op mice are smaller

than normal littermates, have a lower birth weight, have no teeth,
and have bones typical of osteopetrosis which are devoid of
osteoclasts.

Because the mice also have low numbers of circulating

moncytes and macrophages, the M-CSF gene was implicated in the
disease etiology. Wieslaw-Jedrzejczak et al. eventually
demonstrated that tissues from op/op mouse were devoid of M-CSF
whereas op/+ and +/+ littermates had normal levels of the
hormone206. Furthermore, only the larger 4.6 kB mRNA species
was detected in op/op mice, whereas normal littermates expressed
both 2.3 and 4.6 kB species.

Eventually, a stop codon was identified

in the middle of an important reading frame in the op/op mouse

STOP

Figure Il.xiv. The wild vs. op/op M-CSF amino acid sequence from residues #5468 of exon 4. An insertional mutation of thymidine in a codon for leucine produces
a codon translates for serine and produces frameshift mutations distally until a
TGA stop codon is read producing a truncateded molecule unable to act as a ligand
for the M-CSF receptor.

mRNA for M-CSF, an oligonucleotide error which precluded
production of the hormone (Figure Il.xiv)212.

Administration of

recombinant murine M-CSF replenished osteoclasts in the op/op mice

and cleared the animals of disease.

These experiments demonstrated

both the importance of a specific hematopoetin in the etiology of a
particular disease as well as the role such hematopoetins may play in
normal bone physiology.

F. Thesis Investigation.

The discussion of TGF-6 and the cytokines above points to the
diverse activities of these hormones in cell growth and regulation.
Many of TGF-B's roles include modulating the effects of other
growth factors.

Mineralized tissue may be

unique in this regard

because bone is not only a large source of active TGF-B but of
several osteoblast-derived growth factors.

Any relationship

between active TGF-B and the regulation of osteoblast-derived
cytokine

production,

however,

as

not

yet

been

defined.

Understanding the regulation of osteoblast-derived cytokine
production may help towards describing the function of these growth
factors in vivo.
This thesis presents experiments which tested the affects of
TGF-B on fetal rat osteoblast production of IL-1, IL-6, GM-CSF,
and M-CSF, as assayed with known growth factor-dependent cell
lines.

This work presents a novel description of growth factor

interactions which may have relevance to the paracrine regulation of
bone remodeling and hematopoesis in vivo.

m. MATERIALS AND METHODS

A. Cell Preparation.
1. Primary cultures of fetal rat osteoblasts.

Fetal rat calvaria were

obtained at 22 days gestation and isolated under sterile conditions. Primary cells
vvere obtained through a sequential collagenase digestion procedure as detailed by
Wong and Cohn208# After a 20 minute digestion in 3 ml isotonic salt with 0.1 %
collagenase, 0.05 % trypsin, and 4mM EDTA at room temperature the first
eluted cell suspension was saved as population #1. The eluant obtained through a
second 20 minute digestion was discarded, but the cells recovered from the 3rd,
4th, and 5th digestions were saved, and pooled, as populations # 3-5.

Analysis of

known cellular markers for osteoblasts (alkaline phosphatase activity, response to
parathyroid hormone, synthesis of collagen I & III) has previously determined
that cells from populations #3-5 are predominantly

I

(> 95%) osteoblasts and

osteoblast precursors"^ As described in III.C.5 and V.ii, osteoblast preparations
were assayed for interleukin-1 activity (IL-1) to determine the presence of
contaminating macrophages which constitutively release IL-1. No significant IL1 activity was found in any preparation of osteoblast CM (data not shown). The
LBRM assay for IL-1 activity can detect IL-1 concentrations down to 10
pg/ml213b. The absence of detectable IL-1 activity is therefore suggestive that the
osteoblast preparations were reasonably devoid of macrophage activity (data not
presented).
All preparations of primary osteoblast cultures were kindly provided by
Dr. M. Centrella, St. Francis Hospital, Hartford, Connecticut.

2. C3H/HeJ mouse bone marrow cells. Total bone marrow cell cultures
were obtained from a C3H/HeJ mouse (Jackson Laboratories, Maine).

The

animal was killed with cervical dislocation. The two hind legs were cleaned with

50% ethanol and shaven.

The femurs were isolated and removed to a sterile

field. The metaphyses of each bone were removed and the indwelling marrow
cells expelled with PBS introduced by a 10 cc syringe. The cells were collected,
washed three times in PBS and counted.

The cells were placed into Costar

culture plates for experimentation as described in IV. D and maintained in
Dulbecco's modified Eagles medium (DMEM) with nonessential amino acids,
penicillin, streptomycin, 20 mM HEPES, 100 ug/ml L-ascorbic acid, and 10 %
fetal calf serum (FCS).
All preparations of C3H/HeJ mouse bone marrow cells were made by the
author.

B. Preparation of Conditioned Medium (CM).

Cells suspensions were

plated out in 6 well tissue culture plates (Costar) at a concentration of 5 x 10^
cells/well, and grown in Dulbecco's modified Eagles medium (DMEM) with
nonessential amino acids, penicillin, streptomycin, 20 mM HEPES, 100 ug/ml Lascorbic acid, and 10 % fetal calf serum (FCS). Cells were cultured in the serum
containing media until the cells reached sub-confluence, at which time the media
was withdrawn, the cells washed twice in phosphate buffered saline (PBS), and
serum-free media added to the culture wells.
serum-free media 60-72 hours until

The cells were maintained in the

confluent.

The media was removed, the

cells washed twice with PBS, and fresh serum-free media was returned to the
wells along with the appropriate inducing agents for each experimental protocol
as noted in the text.

A typical experiment maintained the cell monolayers for 48

hours at 37°C in 5% C02-

Following the culture period, the CM was collected,

filtered through Millipore symige-held membranes, and frozen at -20.C.
A series of 'priming' experiments are described and presented in sections
IV. v and xv and were conducted as follows: Confluent, serum-deprived cells
were exposed to a single agent in serum-free media for a 2 hour time period.

The cells were then washed twice with PBS and a second agent was then provided
to the cells in fresh serum-free media for 46 hours. The supernatant was then
removed and saved as a CM and analyzed for cytokine activity as described below
in sections IV. v and xvi.

Appropriate control CMs were obtained for each

experiment. For example, if a cell group was exposed to TGF-13 for 0-2 hours
and then LPS for 2-48 hours, the three experimental controls would include (1)
CM from cells exposed to serum-free media for 0-2 hours and again for hours 248, (2) CM from cells exposed to TGF-6 for 0-2 hours and then to serum-free
media alone for 2-48 hours, and (3) CM from cells exposed to serum-free media
alone for 0-2 hours and then to LPS for 2-48 hours.
A series of 'time course' experiments were conducted in which confluent
osteoblasts were prepared as described above and then treated with indicated
agents in fresh serum-free media.

Conditioned media was then removed and

saved for later analysis after 6, 22 and 48 hours of treatment.

A second

experiment used the same protocol but analyzed CMs removed after 1, 2.5 and 6
hours of treatment.
All CMs were prepared by Drs. M. Centrella and T. McCarthy, St. Francis
Hospital, Hartford, Connecticut unless otherwise specified in section IV.
C. Cytokine Assays.

1. Granulocyte-Monocyte Colony Stimulating Factor (GM-CSF).

GM-

CSF activity was determined using the HT-2 T-cell assay as was initially reported
by Kupper et al.116b.

Briefly, as outlined in table Ill.i below, HT-2 cells were

maintained in suspension in continuous culture in Eagles Hanks Amino Acid
(EHAA) medium with 10% fetal bovine serum (FBS), penicillin, and
streptomycin. Cells were washed three times in phosphate buffered saline (PBS)
(Gibco, Grand Island, N.Y.) with 2% FBS, resuspended in EHAA with 10% FBS,
and plated into wells of 96 well tissue culture plates (Costar) at a concentration of

5 6

2 x 1()4 cells/well. Varying concentrations of test CM were added to the cells. A
final volume of 200 pi was achieved with complete media.
were incubated for 48 hours at 37 °C in 5% CO2.

Triplicate cultures

HT-2 cells proliferate in

response to GM-CSF as well as Interleukin-2 (IL-2). Recombinant human
interleukin-2 (r-hu IL-2) is, therefore, used as a positive control in the HT-2
assay.
HT-2 cells respond to GM-CSF, IL-2, and IL-4H6c. IL-2 and IL-4 activity
has never been identified in the preparations of osteoblasts used in the these
present studies (M. Horowitz, unpublished).

Osteoblasts do not produce IL-2

suggesting that HT-2 cell-inducing activity in a given CM is due to the presence
of GM-CSF.

To test for the presence of GM-CSF in a given CM,

a goat

antibody against rat GM-CSF was used at a concentration of 1:1000 in assays as
specified in section IV. iv. The antibody was made and provided by Dr. J.

b)

J

Figure IEI.i. Preparation of conditioned media, a) Parietal bones dissected from fetal rat pups at
22 days gestation, b) Bones digested with .1% collagenase to obtain populations of osteoblasts, c)
Osteoblasts grown to confluence and serum-deprived for 24 hours, d) Reagents added to cultures
for given time interval, e) Supernatants collected as conditioned media (CM).

Schreurs, DNAX (Palo Alto, California). The antibody preparation against GMCSF does not cross-react with IL-2, IL-3, G-CSF, M-CSF, or any other known
cytokine (J. Schreurs, unpublished).
HT-2 cells were grown for 44 hours, pulsed with 1 p.Ci/well of ^HThymidine (Specific Activity: 70-85 Ci/mmol) (New England Nuclear,
Cambridge, Mass.) and harvested at 48 hours onto glass fiber filters using an
automated sample harvester (Cambridge Technologies, Cambridge, Mass.).
Incorporated radioactivity was measured with a Beckman scintillation
spectrometer (Fullerton, Ca.).

Data are presented as the mean of the triplicate

cultures ± the standard error (SE).

All data presented are representative of

multiple experiments. All assays for GM-CSF were made by the author.

2. Interleukin 6 (IL-6).

IL-6 activity was determined using the IL-6

dependent hybridoma developed by Aarden et al. and Landsorp et al. known as B
13.29, or the subclone, B-91’121. B-9 cells are 15-20% more sensitive than the B
13.29 parent line to Hybridoma Growth Factor (HGF) as assayed by Aarden et
ail, 121

B-9 ceps win proliferate

in response to a minimum of .06-. 125

units/ml HGF (IL-6) and maximally respond to ~2 units/ml HGF (IL-6)1.

The

cell line does not proliferate in response to other cytokines and is presumed IL-6
dependent1’!2!.

B-9 cells were maintained in EHAA medium, penicillin,

streptomycin, glutamine, and 2% FBS. The cells were washed three times in PBS
with 2% FBS, resuspended in EHAA with 2% FBS, and plated in 96-well tissue
culture plates at a concentration of 104 cells/well. Varying concentrations of test
CM were added to the cells, and a positive control was established using the
supernatant from the human bladder carcinoma cell line, T24.

Cells were grown

for 56 hours and then pulsed with 1 jiCi/well of ^H-Thymidine (Specific Activity:
3-4 Ci/mmol) (New England Nuclear, Cambridge, Mass.) and harvested at 72
hours with an automated sample harvester (Cambridge Technologies, Cambridge,

Mass.), and measured for radioactivity with a Beckman scintillation spectrometer
(Fullerton, Ca.). Data was presented as the mean of each triplicate ± the SE.
A monoclonal mouse antibody against IL-6 was prepared by Lansdorp et
al.121. The antibody was used in experiments to block the activity of CMs which
had B-9 cell inducing activity. The antibody failed to block the activity of CMs
over a broad range of concentrations and there was some evidence that the
antibody preparation itself was

stimulatory for B-9 cells (data not presented).

The presence of IL-6 in given CMs could not be thus confirmed. However, the
specificity of B-9 cells for IL-6-dependent growth is highly suggestive that the
activity of a given CM is due to IL-6. In subsequent experiments the stimulatory
activity of the CM was confirmed using a second neutralizing anti-IL-6-antibody
(M. Horowitz, pers. comm.).
All assays for IL-6 were made by the author.

3. Macrophage Colony Stimulating Factor (M-CSF). M-CSF activity was
determined using the growth factor dependent macrophage cell line, BAC

1.2F5139b,184

Morgan reported that BAC cells proliferate in response to a

minimum of 50-100 units/ml CSF-1 (M-CSF) with >98% viability and maximally
proliferate in response to -3000 units/ml CSF-1. BAC cells have not been shown
to proliferate in response to other cytokines except M-CSF139b

BAC 1.2F5 cells

were maintained in Iscoves medium supplemented with 10% FBS and 10% L929
cell CM as a source of M-CSF. Cells were washed in PBS and plated into 96 well
tissue culture plates at a final concentration of 1 X 10^ cells/well. Varying
amounts of CM were added to each well. The cells were cultured for a total of

72 hours, pulsed with 1 jiCi/well of 3H-Thymidine (3-4 Ci/mmol specific
activity) for the last 16 hours of culture.

BAC cells are adherent and were

therefore prepared for harvesting by discarding the cell supernatants, and
washing each well twice with 50 p.l/well of PBS. Cells were swollen open by the
addition of 50 pl/well of H20, incubated for five minutes, and then by the

addition of 50 jllI of 1 N NaOH for five minutes. Lysate from each well was then
harvested onto glass fiber filters using an automated sample harvester
(Cambridge Technologies, Cambridge, Mass.). Radioactivity was measured using
a Beckman scintillation spectrometer (Fullerton, Ca.), and the data was presented
as the mean ± the SE of each triplicate.
All assays for M-CSF were made by the author.

4. Interleukin-1 (IL-1). IL-1 activity was determined using the LBRM
33-1 A5.47

(LBRM) T-cell lymphoma and CTLL-2/CT-6 (CTLL) T-cell

lines212b.

Zlotkin et al. originally reported that LBRM cells

proliferate

maximally to co-stimulation by IL-1 (25% supernatant from P388 D1 SN
macrophages, a DBA/2-derived tumor line, Amer. Type Cult. Collec.) and
phytohemagglutiinn (PHA) (50 jj,g/ml)2113b,
maximum of 640 units/ml Interleukin-2 (IL-2) in

The LBRM cells produce a
213b

response

One unit of IL-2

is defined as the minimum dilution of CM capable of achieving 90% viability of
4000 HT-2 cells for 24 hours212b.
The LBRM assay for IL-1 activity is performed in two parts:

First, the

IL-1 responsive T-cell lymphoma cell line LBRM 33-1A5.47 is cultured in the
presence of

osteoblast-derived CMs.

After 12 hours the supernatants are

removed and filtered. Second, the CTLL-2/CT-6 T-cell line is then cultured with
the filtered CMs. The LBRM cells produce IL-2 in response to any IL-1 in the
test CMs. The CTLL cells proliferate in response to the IL-2 in the supernatants
derived

from the LBRM cell culture.

CTLL cells also respond to high

concentartions of IL-4 which LBRM cells have not be shown to produce213b.
LBRM cells are maintained in EHAA with 10 % FBS.

The cells were

washed in PBS three times and resuspended in 96 well tissue culture plates with
the CMs at varying dilutions.
presence

The cells were cultured for 12 hours in the

of phytohaemagglutin

(PHA)

at

1:200 final

Recombinant IL-1 was included as a positive control.

concentration.

At 48 hours, the wells

were mixed, and the plates were spun at 1500 r.p.m. for 3 minutes to pellet cells.
50 pi from each well was removed and placed into wells of a 96 well plate, with
CTLL cells plated at a concentration of 2 x 10^ cells/well. The CTLL cells were
cultured for 44 hours and then pulsed with ^H-Thymidine

(spec, activ. 70-85

Ci/mmol) for a final 4 hours, harvested with an automated sample harvester onto
glass fiber filters (both Cambridge Technologies, Cambridge, Mass.), and
radioactivity was measured using a Beckman scintillation spectrometer
(Fullerton, Ca.).
All assays for IL-1 were made by the author.
TABLE IH.i
CYTOKINE
ASSAY CELL

GM-CSF
HT-2

CELL TYPE

T-CELL

MEDIA

EHAA

M-CSF

IL-6
B-9

BAC

Hybridoma
EHAA

Macr.

12/48

72

72

PULSE TIME (hours)

4

16

16

T24

Macr./T-cell
RPMI/EHAA

48

IL-2

LBRM/
CTLL

ISCOVE

ASSAY TIME (hours)

POSITIVE
CONTROL

IL-1

L929

-/4

IL-1/2

D. RNA Analavsis
1. RNA isolation.

Total cellular ribonucleic acid was isolated according to

the procedures of Chirgwin et alA^b.

Briefly, confluent monolayers of

osteoblasts were lysed with a guanidinium lyze buffer (GTC) [4 M Guanidine
Thiocyanate (American Bioanalytical), 0.5 % NaN-lauryl sarcosine (Sigma), 1 M
Na Citrate, pH 7.0, 0.7 % v/v 2-mercaptoethanol, and 0.33% v/v 30% anti-foam

A (Sigma), all Millipore-filtered three times and stored at 4° Cj.

Lysate was

drawn into a 10 ml syringe through a 23-gauge needle to shear DNA:DNA
hybrids.

Sheared lysate was then layered on top of a 3 ml 5.7 M Cesium

Chloride solution (Gallard-Schlesinger Ind.), with 25 mM Na Citrate, pH 5, in a
15 ml SW 41 polyallomer tube (Beckman). Tubes were then topped off with
guanidinium lyse buffer. Tubes were centrifuged in a SW 41 rotor for 20 hours
at 35,000 r.p.m. at 20° C.

Supernatant was removed and discarded leaving a

clear pellet of crude RNA.

Pellet was

resuspended in 400 pi of

Diethylpyrocarbonate-treated (500 pg/ml) (Sigma) H2O, and 1/10 volume 4 M
NaCl was added.

The solution was transferred to micro-centrifuge tubes and

RNA extracted with an equal volume of water-saturated phenol. The acqueous
(upper) layer was removed and placed into a new micro-centrifuge tube.

2.5

volumes of cold 100% ethanol was added to tubes and solution was frozen on dry
ice (-70° C).

Tubes were spun for 20 minutes in a microcentrifuge, and the

supernatant was withdrawn and discarded. Procedure was repeated to resuspend
and rextract RNA a second time to rid RNA of any residual cesium chloride.
After a second extraction, RNA was resuspended in 50 pi of DEP'd H20, 1:1000
dilutions of 1 pi aliquots from each sample were made to test for optical density
at wave lengths of 260 and 280 nm using a Spectronic 601 spectrophotometer
(Milton Ray Company).

For RNA, 1.0 units of OD at 260 nm corresponded to

40 pg/ml of RNA. A ratio of 0D 260/280 approaching 2.0 indicated reasonable
purity of RNA preperation.

RNA samples were prepared by the author and

Andrea Fields, Yale University.
2. RNA electrophoresis. RNA preparations were brought to concentrations
of 2 mg/ml. 10 pi (20 pg) of RNA was then mixed with 20 pi of glyoxal buffer
[1 M glyoxal (Eastman Kodak), 0.1 % SDS (Boehringer-Mannheim), 10 mM
Phosphate buffer (pH 6.8 mono/dibasic), 50 % vol/vol Spectrograde DMSO,
brought to volume with DEP'd H20] and incubated at 50° C for one hour. 15 pi

(10 jig) RNA was loaded into each lane of a 1.5 % agaorse gel made up in 10 mM
Phosphate buffer, and was electrophoresed into the gel matrix body at 0.5
volts/cm.

Once the RNA front was in the body of the gel, the voltage was

increased to 5 volts/cm until the gel front had traversed at least 60 % of the gel
length. The elctrophoresis was then stopped. Electrophoresis was performed by
the author and Andrea Fields, Yale University.
3.

Northern blotting. After electrophoresis, gel was removed and placed

upside down on an ethanol/0.3 % H2O2 cleansed industrial sponge soaked in a pan
of 20 X SSC (3M NaCl, 0.3M Na citrate, pH 7.0).

A square of Zeta bind

(Amersham) blotting paper was cut to fit the gel, was soaked in H2O one minute
to wet, and was placed onto the gel.
between blot and gel interface.

A pipette was used to force out bubbles

A piece of filter paper (Whatman) of the same

proportions as the gel was wetted in H2O and placed on the blotting paper
followed by five similar but dry pieces of filter paper.

Two Diaper-liners

(Johnson & Johnson) were then placed on top of the filter paper, and a plastic
plate placed on top of liners. A 500 gm bottle was placed on plate as a weight.
The apparatus was left in place for 15-20 hours and then the Zeta-bind was
removed, and briefly rinsed for 15 seconds in 2X SSC and then let dry for 10
minutes. Blotted RNA was cross-linked with a hand-held short-wave ultraviolet
light source for 3 minutes. Hybrization was performed by the author and Andrea
Fields, Yale University.
4. Radiolabeling of cDNA IL-1R probes. Probes of complimentary DNA
(cDNA) for murine IL-1R were labeled with 32p_ATP/CTP by random priming
of a IL-1R insert. The IL-1R cDNA was carried in a pGEM-2 vector and was
kindly provided by Simone Carding, Yale University. The IL-1R 300kb insert
was prepared and radiolabeled by Andrea Fields, Yale University after double
digestion with ECOR1 and Pstl for 30 minutes at 37° C.

The fragment was

isolated using a Gene Clean kit (Boeringer-Mannheim) protocol and radiolabeled

I

)

using the Random Priming kit (Boehringer-Mannheim) protocol.

Briefly, the

linear piece of cDNA was denatured by boiling for 5 minutes, and 50 ng of
cDNA was placed in a 1.5 ml tube. To this was added 1 pi each of dGTP and
dTTP (50 mM stcok), 2 pi reaction buffer ("hexanucleotide mixture in 10 x
concentrated reaction buffer"), 50 pCi each of 32P dCTP and 32p dATP (New
England Nuclear), and 1 pi of Klenow fragment (2 u/pl).

The mixture was

placed in a 37.0 °C water bath for 30 minutes. A second 1 pi of Klenow (2 u/pl)
was added to the reaction and the reaction was left overnight at room temperature
(22.5° C).

The reaction was stopped with enough kit stop buffer to increase

reaction volume to 100 pi.

Radio-labeled cDNA was isolated after passing

mixture over a Sephadex G-50 spin-column centrifuged at 1500 r.p.m. for 5
minutes.
5. Hybridization.
10 mis of 1%

Filters were pre-hybridized for 30 minutes at 65° C in

Bovine Serum Albumin

(Fraction V, Sigma),

7% Sodium

Dodecyl Sulfate (Boehringer-Mannheim), 500 mM Sodium Phopshate buffer,
and 25 mM EDTA, all sealed in a Seal-a-meal® bag.

Radionucleotide-labeled

probe was added at 1-10 x 106 cpm/ml and hybridized for 15-20 hours at 65° C.
Following hybridization, fluid was drained and disposed and blot was washed
twice in 65° C Wash buffer A (5% SDS, 0.5 % BSA, 50 mM Sodium Phosphate
Buffer, 2.5 mM EDTA) and then twice in buffer A for 15 minutes at 65° C each.
A second buffer of 1% SDS, 50 mM Sodium Phosphate buffer, and 2.5
mM EDTA (Wash B) was used to wash the blot three more times at 65° C. Blot
was then briefly dried by blotting with Kim-wipes and then placed in an envelope
of saran wrap.

Biot was placed in an X-ray exposure holder (Kodak) and

covered with one piece of X-OMAT AR type film (Kodak).

An intensifying

screen (Parker X-ray) was placed on film and holder was sealed, and placed in a
70° C freezer until exposure time as noted in the text.
Hybridization was performed by the author and Andrea Fields, Yale University.

IV. RESULTS
STUDIES OF GM-CSF: TGF-B and LPS

IV.i. TGF-B does not induce the release of GM-CSF.

To determine

whether TGF-B could induce GM-CSF release from osteoblasts, various
concentrations of TGF-B were added to serum-deprived osteoblasts.

As

described in III.B, the conditioned media (CM) was collected after 48
hours and tested for GM-CSF activity with the T-cell line HT-2.

As

presented in figure IV.i, 0.1-10 ng/ml of TGF-B did not induce GM-CSF
activity in various dilutions of tested CMs, compared to both experimental
controls (no TGF-B) and to assay controls (no tested CM).

rhulL-2

Figure IV.i. HT-2 cell assay for TGF-B-induced GM-CSF activity in test CMs. Included
are negative test controls (no TGF-B), positive assay controls (recombinant human
Interleukin-2), and negative assay controls (no CM).

IV.ii. Lipopolvsaccharide (LPS) induction of GM-CSF release is dosedependent. Although 10 pg/ml of LPS had been known to induce GM-CSF
release from osteoblasts, the effect of lower doses of LPS on osteoblasts
was unclear.

As described in III.B,

serum-deprived osteoblasts were

exposed to LPS at concentrations of 10 ng/ml to 10 pg/ml for 48 hours.
CMs were tested for GM-CSF activity using the HT-2 T-cell assay.

As

shown in figure IV.ii below, LPS, at concentrations greater than 1.0 pg/ml,
induced considerable GM-CSF activity whereas LPS at concentrations less
than 1.0 pg/ml induced no detectable GM-CSF activity.
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Figure IV.ii. HT-2 assay for GM-CSF activity of CMs from osteoblasts cultured with
different concentrations of lipopolysaccharide (LPS). Included are a test control (no LPS),
a negative assay control (no CM), and a positive assay control (recombinant human IL-2).

IV.iii. TGF-B and low dose LPS svnergize for release of GM-CSF from
osteoblasts.

From the previous experiment, it had been determined that

neither 10 ng/ml of TGF-B nor LPS at concentrations < 100 ng/ml induced
GM-CSF release from osteoblasts. To test whether TGF-B would change
the response of osteoblasts to sub-stimulatory levels of LPS (<100 ng/ml),
osteoblasts were exposed to either TGF-B alone, to substimulatory LPS
alone (10 or 100 ng/ml), or to TGF-B (10 ng/ml) together with LPS (10 or
100 ng/ml). As presented in figure IV.iii below, neither TGF-B alone nor
LPS alone induced GM-CSF activity in CMs. However, TGF-B combined
with LPS synergized to induce a substantial increase in GM-CSF activity.

Figure IV.iii. HT-2 assay for GM-CSF activity of CMs from osteoblasts cultured with
either TGF-B alone or with LPS alone, or with TGF-B and LPS together. Included are a
negative assay control (no CM) and a positive assay control (10% rhIL-2). 1=LPS at 10
ng/ml, 2=LPS at 100 ng/ml, 3=TGF-B at 10 ng/ml, 4= LPS at 10 ng/ml + TGF-B at 10
ng/ml, 5=LPS at 100 ng/ml + TGF-B at 10 ng/ml. a=2.5% CM, b=5% CM, and c=10%
CM. 10% negative experimental control CM (no agents) induced 1.8 x 103 3H-TdR cpm.

IV.iv. TGF-B/LPS-induced GM-CSF activity in tested CMs can be
neutralized with goat antibody against mouse GM-CSF.

To determine

whether the observed increases in GM-CSF activity of CMs, as presented in
figure IV.iii, was specifically due

to GM-CSF, the same CMs were re¬

tested in the HT-2 assay with either supplemental goat antibody to mouse
3HTdR cpm x

1

Figure IV.iv. HT-2 assay for GM-CSF activity of 10% CMs co-cultured with either heatinactivated goat serum or goat antibody to mouse GM-CSF. Slashed histograms represent
samples assayed in the presence of a 1:1000 dilution of the goat antibofy and the clear
histograms represent samples assayed in the presence of a 1:1000 dilution of the inactivated
serum. Background controls include normal goat serum alone (NGS) and goat anti-mouse
GM-CSF alone ( GM-CSF). Other controls not presented include 10% recombinant
human IL-2 (42450 ±320 cpm) and assay background activity (450 ± 35 cpm). Standard
deviations are also represented.

GM-CSF or with heat-inactivated normal goat serum. As shown in figure
IV.iv above, the TGF-B /LPS-induced increase in GM-CSF activity was
blocked to within background levels by goat anti-mouse GM-CSF but not
by normal heat-inactivated goat serum.

IV.v. TGF-B/LPS svnergv for GM-CSF release is TGF-B dependent. As
described in III. B, a series of 'priming' experiments were conducted in
which osteoblasts were exposed to either TGF-B alone for two hours, or to
low-dose LPS alone for two hours. The cells were then washed, and then
incubated with the complementary synergen for the next 46 hours (Cells
incubated with TGF-B for hours 0-2 were exposed to LPS for hours 2-48).
As shown below in figure IV.v., there was no GM-CSF activity in CMs
from cells cultured with LPS alone for hours 0-2 and then with TGF-B for

3FITdR cpm x 10 3
0-2 hrs

TGFp 400 pM
TGFp 400 pM
TGFp 400 pM
LPS 1 pg/ml
LPS 100 pg/ml
LPS 1 pg/ml
LPS 100 pg/ml

Figure IV.v. HT-2 assay for GM-CSF activity in 10% CMs from osteoblasts 'primed'
with either TGF-B or with LPS and then exposed to the corresponding synergen. Included
are negative (assay cells) and positive assay controls (10% rhEL-2) as described above.

hours 2-48. However, cells incubated with TGF-B for hours 0-2, and then
LPS for hours 2-48 produced CMs with the high GM-CSF activity seen in
previous experiments.

IV.vi.a/b. Most of the TGF-B/LPS-induced release of GM-CSF occurs
between hours 2.5 and 6. TGF-B and LPS induced large increases in GMCSF activity of CMs after 48 hours of cell treatment, as described above.
To decribe a more complete spectrum of activity, two experiments were
conducted.

In the first (IV.vi.a.), CMs were collected at hours 0, 6, 22,

and 24 and analyzed for GM-CSF activity while the second (IV.vi.b)
analyzed CMs collected at hours 0, 1, 2.5, and 6.0.

As shown below in

figure IV.vi.a. below, CMs at time zero (CMs collected before addition of
agents to media) contained no detectable GM-CSF activity compared to

Figure IV.vi.a. HT-2 assay for GM-CSF activity of indicated 10% CMs. Values not
included are the assay control (850 ± 20), experimental negative control [no agents] (920 ±
15), and experimental positive control [10% recombinant human IL-2] (52250 ± 650).

background samples.

CMs at six hours of incubation contained ten to

twenty times the GM-CSF activity of relevant background samples. CMs at
22 hours incubation contained 15% more activity than 6 hour CMs, and
CMs at 48 hours contained 20% more activity than CMs at 22 hours. LPS
as a single agent induced a small increase in GM-CSF activity in six hour
CMs, but the level of activity plateaued over the next 42 hours. The second
experiment, presented as figure IV.vi.b below, tested CMs at hours 0, 1,
2.5, and 6 to determine GM-CSF release at earlier time points than
discussed in IV.vi.a. As shown below, no GM-CSF activity was detected in

H-TdR cpm x 10

the zero, 1, or 2.5 hour CMs. The 6 hour CMs contained the high GM-CSF

Figure IV.vi.b. HT-2 assay for GM-CSF release over hours 0-1, 1-2.5, and 2.5-6.
Histograms represent the GM-CSF activity for each 10% CM grouped according to time
points._l=Control, 2=LPS at 10 ng/ml, 3=TGF-B at 10 ng/ml, 4=2+3.
Positive assay
control of 10% rec. human IL-2 induced 69,000 ± 550 cpm in HT-2 cells, while a negative
assay control of assay cells alone yielded 650 ± 40 cpm.

activity levels observed previously. The data from IV.vi. a and b suggest
that the effect of TGF-6 and LPS on osteoblasts for GM-CSF release is
obtained after a minimum of 2.5 hours of exposure to the synergens,
maximizes quickly, and is short-lived.
IV.vii. The rate of GM-CSF release is at a maximum between hours 0-6. a
rate 95% higher than the rate of release between hours 6 & 22 and between
22 & 48.
As presented in IV.vi.a, the largest increase in GM-CSF release occurs
between hours 0 and 6, while smaller increases occur over the subsequent
42 hours. This difference is presented in figure IV. vii as the rates of
change in GM-CSF release. As illustrated below, TGF-B and LPS induce
an increase in the rate of GM-CSF release to a maximum between hours
zero and six. The rate of release over the next 16 hours drops 95% to
Acpm/Atime
TGFi

13.

10 ng/ml

Figure IV.vii. Rates of change in GM-CSF release in cells exposed to TGF-B and LPS for
different intervals of time. The incorporated radioactvity in HT-2 cells induced by a given
sample of CM is quantitated as counts per minute (cpm). The increase in cpm value
(Acpm) is divided by the time interval in which a given CM was produced (Atime), either
6 hours, 22 hours, or 48 hours. The ratio of the cpm value of a given CM to the time
value of a given CM is presented as the rate of change (Acpm/Atime) in GM-CSF release.
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levels statistically equivalent to background. Finally, the rate of GM-CSF
release over hours 22-48 remains unchanged from the 6-22 hour release
rate and is essentially background.

STUDIES OF GM-CSF:

TGF-B and PTH

IV.viii. PTH alone does not induce GM-CSF release: PTH > 20nM is a
poor inducer of GM-CSF release in combination with TGF-B. Cells were
cultured with one of four concentrations of parathyroid hormone (.02, .2,
2.0 or 20.0 nM). Additionally, some cells were also incubated with TGF-B
at 10 ng/ml (400 picomolar [pM]).

CMs were collected after 48 hours

incubation and assayed for GM-CSF. As presented in figure IV.viii below,
PTH alone (at any concentration) did not induce significant GM-CSF
release.

FGF-B also failed to increase cytokine release.

Only PTH at a

concentration of 20.0 nM, when combined with 400 pM TGF-B, induced a
significant increase in GM-CSF release.
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Figure IV viii. HT-2 assay for GM-CSF activity of 10% CMs from cells cultured with .02
- 20 nM parathyroid hormone (PTH) alone or with PTH and TGF-B, as indicated. The
assay control (no CM) value was 6275 ± 340, the positive control ( 10% recombinant
human IL-2) value was 32,575 ± 965.

STUDIES OF GM-CSF: TGF-B and Interleukin-1
TV. ix. Low-dose Interleukin-1 alone does not induce GM-CSF release, but
low-dose IL-1 svnergizes with TGF-B to induce a 15-fold increase in GMCSF release.
It was previously known that concentrations of Interleukin-1 (IL-1) greater
than 10 pg/ml induced GM-CSF release from osteoblasts (data not shown),
but the effects of lower doses was unclear.

To test low-dose IL-1, and

whether TGF-B could effect IL-1 action, cells were incubated in either 1,
10 or 100 nanogram (ng) IL-1. Other cells were also exposed to 10 ng/ml
TGF-B (400 pM). After 48 hours of incubation, CMs were collected and
tested for GM-CSF activity. As presented in figure IV.ix, neither 1 or 10
ng/ml IL-1 induced any significant GM-CSF activity in the tested CMs.
3HTdR cpm x 10"3

Figure IV.ix. HT-2 assay for GM-CSF activity of CMs from cells cultured with IL-1 alone
(1, 10 or 100 ng/ml) or EL-1 with TGF-B (10 ng/ml [400 pM]). Experimental control no
agents) included. Assay controls: HT-2 cells alone=3; 10% rhIL-2=78.

Both concentrations of IL-1, however, synergized with TGF-B to produce a
large increase in GM-CSF activity in tested CMs.

IV.x. IL-l/TGF-B svnergv is unchanged bv indomethacin. As described in
III. B, osteoblasts in vitro were exposed to either TGF-B alone or to lowdose IL-1 alone or to both agents together. Additional cells were similarly
cultured but with the addition of the non-steroidal anti-inflammatory agent

Figure IV.x. HT-2 assay for GM-CSF activity in a series of cyclooygenase inhibition
experiments with lO-6 M indomethacin. Agents were added to cell cultures for the period of
time as indicated. Relevant controls are represented as above. Negative assay control
(assay cells alone) induced 7 x 103 3H TdR cpm activity in HT-2 cells while the positive
assay control (10% rhIL-2) induced 68 x 103 3H TdR cpm activity. CMs at 10% dilution.

indomethacin at a concentration of lO6 M.

As shown above in figure

IV.x, there was no GM-CSF activity in CMs from cells cultured with the
IL-1 alone or with TGF-B alone. As expected, TGF-B and IL-1 synergized
to increase GM-CSF release greater than 10 fold. The addition of 10~6 M
indomethacin to the cultures did not change the GM-CSF release response
of the osteoblasts cultured with either IL-1 or TGF-B alone. There was a
slight (<5%) increase in the GM-CSF released by osteoblasts cultured with
all three agents (IL-1, TGF-B, and indomethacin).

IV.xi.

Maximum GM-CSF release by TGF-B/IL-1 synergy is achieved

between hours 2.5 and 6 of stimulation, is rapid, and short-lived. As
discussed above in IV.vi a and b regarding the time-course of TGF-B/LPS
synergy,

the time-course for TGF-B/IL-1

synergy was determined by

analyzing CMs for GM-CSF activity obtained at 0, 1, 2.5, and 6 hours of
exposure to TGF-B alone, IL-1 alone, or to both agents together.
presented in figure IV.xi below,
observed in

As

no or little GM-CSF activity was

CMs at hours 0, 1, or 2.5.

CMs collected at 6 hours of

exposure to both TGF-B and IL-1, however, contained 30 times the activity
of control samples. Although not included below, CMs obtained at 6, 22,
and 48 hours were also tested for GM-CSF activity. Similar to the results
of experiment IV.vi.a above concerning TGF-B with LPS, CMs from hours
22 and 48 showed less than 5% more GM-CSF activity than CMs at hour 6
(not shown). The data of IV.vi a/b (TGF-B + LPS) and IV.xi (TGF-B +
IL-1) suggest that TGF-B synergizes with LPS or with IL-1 to induce GMCSF release from osteoblasts.

The effect occurs after 2.5 hours of

treatment, peaks after about 6 hours of treatment, and declines dramatically
soon thereafter.

Figure IV.xi. HT-2 assay for GM-CSF activity in 10% CMs collected at specified time
points, grouped as histograms. l=Control, 2=IL-1 10 ng/ml, 3=TGF-B at 10 ng/ml, and
4=2+3. Positive control of 10 % recombinant human IL-2 induced 69,000 ± 550 cpm and
an assay background control was 620 ± 40 cpm.

IV.xii. TGF-B increases mRNA levels for the interleukin-1 receptor. To
determine the effect of TGF-B, LPS, and IL-1 on osteoblast mRNA
production, osteoblasts were cultured with 10 ng/ml TGF-B alone, 10
ng/ml IL-1, 10 ng/ml LPS alone, TGF-B + IL-1 (each at 10 ng/ml), or
TGF-B

-r

^PS (each at 10 ng/ml). According to the procedures outlined in

m.D.1-5, samples of mRNA from each treatment group were obtained. 10
jig RNA from each sample were electrophoresed , transferred to
nitrocellulose membranes, and hybridized with 32p_iabeled linear cDNA
for the interleukin-1 cell surface receptor (IL-1R). The autoradiograph

obtained, as presented below in figure IV.xii, indicate that TGF-B may
increase the amount of intracellular mRNA for the IL-1R. IL-1 had no
effect, nor did the synergen increase the amount of IL-1R mRNA when
combined with TGF-B. LPS also had no effect. The data does not indicate
whether TGF-B increases mRNA production or message stability. The data
suggests, however, that the synergy between TGF-B and IL-1 for GM-CSF
release may be achieved, in part, by a TGF-B-mediated upregulation of cell
surface receptors for IL-1.

It
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Figure IV.xii. Effect of TGF-B, IL-1, LPS, TGF-B + IL-1, and TGF-6 + LPS on IL-1
cell surface receptor mRNA levels. 48 hour autoradiograph of mRNA hybridization with a
32P-labeled (random primed) linear strand of cDNA for the IL-1R. Precisely 10 pig of
RNA was electrophoresed in each lane and hybridized with 5-10 x 106 counts/ml of cDNA
probe. l=control, 2=IL-1 10 ng/ml, 3=LPS 10 ng/ml, 4=TGF-B 10 ng/ml, 5=2+4,
6=3+4,7=transformed osteoblast line MC3T3 positive control, 8=resting D-10 T-cell
mRNA, 9=IL-1 (10'7)/ConA (2.5 pg/ml)-stimulated D-10 positive control. A
hybridization control with an unrelated probe was not prepared from this blot. The
specificity of the IL-1R cDNA in previous experiments (data not shown), however,
suggests that the bands represented above are those of the IL-1R. Blot prepared by A.
Fields, Yale University.

A. STUDIES OF INTERLEUKIN-6: TGF-6 and LPS

IV.xiii.TGF-B induces IL-6 release. Osteoblasts were cultured with 10.0
ng/ml of TGF-B for 48 hours. CMs were collected and assayed for IL-6
activity as described in III.C ii.

As shown below in figure IV. xiii, 10

ng/ml TGF-B induced IL-6 activity in dilutions of tested CMs.

Similar

increases in IL-6 activity were observed in repeat experiments, although
the absolute level of IL-6 activity induced by 10 ng/ml TGF-B varied (data
not presented).

These findings are in marked contrast to the results of

figures IV.i and iii which show that TGF-B has no effect on GM-CSF
activity in tested CMs.

Figure IV.xiii. B-9 assay for EL-6 activity of CMs collected from cells incubated with
different concentrations of TGF-B. Negative (0) and positive (+C) controls (media alone
and 1.0% T24 CM, respectively) are included as indicated. Ordinate values are presented
as ^H-Thymidine uptake by stimulated B-9 assay cells. Control=CM without agents.

IV.xiv. IL-6 release is induced bv LPS at concentrations greater than 103
ng/ml. Cells were incubated with LPS at concentrations of 0.1 ng/ml 1.0
ng/ml, 100 ng/ml and in a second experiment, of 103 ng/ml or 104 ng/ml
for 48 hours. CMs were collected and assayed for IL-6 activity using the
B-9 B-cell hybridoma line as descibed in III.C ii.

The experiments are

presented together below in figure IV. xiv for comparison, separated by a
cross-hatch along the x-axis.

As the figure suggests background CM

activity CMs collected after exposure to 104 ng/ml of LPS had twice the
amount of IL-6 activity as assay and test background samples.

LPS

concentrations equal to or less than 103 ng/ml failed to induce any IL-6

HTdR cpm x 10

activity greater than relevant background samples.

Figure IV.xiv. B-9 assay for IL-6 activity in CMs after exposure to different concentrations
of LPS. The negative and positive controls for groups A, B, and C are included as
indicated above. For groups D and E the negative control was 4 x 103 3H TdR cpm and the
positive control ( 1.0 % T24 CM) was 60 x 103 3H TdR cpm. For each histogram,
1=03% CM dilution, 2=.1% and 3=.3%. The x-axis is cross-hatched as described above
to represent the inclusion of data from the second, comparable experiment.
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TV. xv. TGF-B and LPS svner-.ze for IL-6 release from osteoblasts. Cells
were cultured for 48 hours with LPS alone (at four concentrations), with
TGF-B alone (at 10 ng/ml) or with both agents together. Data is presented
in figure IV.xv and illustrate that LPS and TGF-B as single agents stimulate
small or no release of IL-6 activity into CMs.

Cells cultured with both

TGF-6 and LPS, however, produced CMs with large increases in IL-6
activity over background. The most striking increase in IL-6 production
occured in the groups combining TGF-B and the lower LPS concentrations
(10 and 100 ng/ml). These two groups of CMs had IL-6 activity similar to
the groups combining TGF-B and higher LPS concentrations (103 and 104
ng/ml).
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Figure IV.xv. B-9 assay for IL-6 activity in CMs after exposure to different concentrations
of LPS alone, TGF-B alone, and to both agents together for 48 hours. A negative
experimental control is included. Negative assay control (B-9 cells alone) = 5 x 103 3HTdR. Positive assay control (1% T24 CM) = 48 x 103 3H-TdR cpm. CMs tested at .3%

IV.xvi. Release of IL-6 from osteoblasts is more dependent upon TGF-B
than upon LPS. A series of 'priming' experiments were carried out

as

described in III. B, and similar to the experiments with GM-CSF in IV.v.
Data from IV. xv suggested that for the induction of IL-6 activity, low
dose LPS may interact with TGF-B as productively as higher dose LPS.
The concentration of LPS used in IV.xvi was therefore lower than that
used in experiment IV. xv in order to test the low concentration limit of
LPS to synergize with TGF-B.
TGF-B as the 'priming' agent: Data is presented below in figure
IV.xvi and illustrates that cells exposed to TGF-B

for hours 0-2

manifested little enhancement of IL-6 activity in CMs. Similarly, LPS at 1
pg/ml and 100 pg/ml for hours 2-48 also did not induce IL-6 release.
However, cells first exposed to TGF-B for hours 0-2, washed and then
exposed to 1 or 100 pg/ml of LPS for hours 2-48 produced CMs with high
IL-6 activity.
LPS as the 'priming' agent: Cells exposed to 1 pg/ml or 100 pg/ml of
LPS for hours 0-2 did not produce CMs with increased IL-6 activity.
Similarly, cells exposed

to TGF-B for hours 2-48 also failed to show

increases in IL-6 release. Cells exposed to 1 pg/ml of LPS, washed and
then exposed to 10 ng/ml of TGF-B produced CMs with two- to three-fold
the IL-6 activity of background samples. Cells exposed to 100 pg/ml of
LPS, washed and exposed to 10 ng/ml of TGF-B produced CMs with higher
IL-6 activity.
The data in figure IX. xvi suggest (1) that cells can be 'primed' with
TGF-B and activated by LPS for IL-6 release and (2)
'primed' by

cells can also be

LPS, in a dose-dependent manner, for IL-6 release. These

results are in contrast with the results of IV.v in which GM-CSF release
was only obtained after cell 'priming' with TGF-B. LPS in IV.v failed to
primed cells for GM-CSF release.
3HTdR cpm x 10‘3
0-2 hrs.

TGF-p

10 ng/ml

LPS 1 pg/ml
LPS 100 pg/ml

LPS 1 pg/ml
LPS 100 pg/ml

Figure IV.xvi. B-9 assay for IL-6 activity of CMs from cells 'primed' with either TGF-B
or LPS, and then exposed to the corresponding synergen. Experimental controls are
included. Negative and positive (1.0 % T24 CM) assay controls for this experiment were 7
x 103 3H-TdR and 60 x 103 3H-TdR, respectively. CMs tested at .3 % dilution.

B. STUDIES OF INTERLEUKIN-6: TGF-B and IL-1

IV.xvii. Low-dose IL-1 alone does not induce IL-6 release but low-dose
IL-1 svnergizes with TGF-B to induce a 12-fold increase in IL-6 release.
To test the effect of lower doses of IL-1 on IL-6 release and the effect of

i

1
TGF-B on IL-1 activity, cells were cultured with either IL-1 alone (1, 10
or 10 ng/ml) or with IL-1 and TGF-G (10 ng/ml).

CMs were collected

after 48 hours, and tested for IL-6 activity. As presented below in figure
IV.xvii, low-dose (1 ng/ml) IL-1 did not induce IL-6 activity in tested
CMs.

However, 1-100 ng/ml IL-1 synergized with TGF-G to induce a

HTdR cpm x 10~3

large increase in the IL-6 activity of tested CMs.

Figure IV.xvii. B-9 assay for IL-6 activity of CMs from cells cultured with either IL-1
alone (1, 10 or 100 ng/ml), TGF-G alone (10 ng/ml) or with IL-1 and TGF-B together .
Negative (0) and positive (+C: 1.0 % T24 CM ) assay controls are included as described in
III.B and table IILi. Experimental background control (no agents) was 1 x 10^
T-dR
cpm. All CMs tested at 0.3 % dilution.

IV.xviii.

IL-l/TGF-G synergy for IL-6 release is not affected by

indomethacin exposure.. Prostaglandins are potent inducers of IL-6 release

and may mediate at least part of IL-1 induced bone resorption.

To

determine whether prostaglandin production by cells derived from rat
parietal bone played any role in the observations presented above the
following experiment was conducted. Osteoblasts in vitro were exposed to

3HTdR cpm x 10'3
IL-1

TGF-P

10 ng/ml

10 ng/ml

10 ng/ml

10 ng/ml

10 ng/ml

10 ng/ml

10 ng/ml

10 ng/ml

Figure IV.xviii. B-9 assay for EL-6 activity in a series of cyclooxygenase inhibition
experiments with indomethacin. Agents were added to cell cultures for the period of time as
indicated. Relevant controls are included as indicated: Negative assay control= 0, positive
asay control (1.0% T24 CM) =+C. CMs tested at 0.3 % dilution.

either TGF-6 alone or to low-dose IL-1 alone or to both agents together.
Additional cells were similarly cultured but with the addition of the non¬
steroidal antiinflammatory agent indomethacin, a potent inhibitor of
prostaglandin production. As shown above in figure IV.xviii, there was no
IL-6 activity in CMs from cells cultured with the IL-1 alone or with TGFB alone. As expected, TGF-B and IL-1 synergized to increase IL-6 release
>10 fold. The addition of indomethacin to the cultures did not change the
IL-6 release response of the osteoblasts cultured with either IL-1 or TGF-B
alone.

There was a slight (<5%) increase in the IL-6 released by

osteoblasts cultured with all three agents (IL-1, TGF-B, and indomethacin).

IV.xix.a./b. Most of the TGF-B/svnergen-induced release of IL-6 occurs
between hours 0-6. specifically, between hours 2.5 and 6.

TGF-B/LPS

and TGF-B/IL-1 induced large increases in IL-6 activity of CMs after 48
hours of cell treatment, as described above in IV. xv, xvi and xvii.
decribe a more complete spectrum of activity,

To

CMs were collected at

hours 0, 6, 22, and 48 of TGF-B/synergen treatment and analyzed for IL-6
activity as described in III. C 2. A second experiment collected CMs at
hours 0, 1, 2.5, and 6 hours after TGF-B/synergen exposure.

As shown

below in figure IV.xix.a below, CMs at time zero (CMs collected before
addition of agents to media) contained no detectable IL-6 activity compared
to background samples. IL-1 alone failed to induce IL-6 activity at any
time point. TGF-B alone induced no activity in IL-6 activity after 6 and 22
hours of treatment but

induced activity after

48 hours of treatment.

TGF-B and IL-1 together, however, induced a large increase in IL-6
activity at 6 hours with a 15% increase between hours 6 and 22.

All 48

hour CMs are essentially 22 hour CMs which remain in culture dishes for
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Figure IV.xix.a. B-9 assay for IL-6 release over hours 0-6, 6-22, and 22-48 of exposure to
TGF-B alone, LPS alone, IL-1 alone, TGF-B with LPS, or TGF-B with EL-1. Ordinate
values are presented ^s the counts per minute of 3H-Thymidine incorporation by B-9 cells
after culture with a given .3% CM sample. Abscissa! values are the length of time of CM
exposure to a given agent or agents. Negative and positive (1.0 % T24 CM) assay controls
were 5 x 103 3H-TdR cpm and 85 x 103 3H-TdR cpm, respectively.
Negative
experimental control at each time point was always less than 5 x 103 3H-TdR cpm.

an additional 26 hours.

It was therefore noteworthy that there was an

apparent decrease in IL-6 activity in 48 hour CMs from 22 hour CMs, as
presented in figure IV. xix a. This difference may not accurately reflect
true changes in IL-6 quantity in 48 hour CMs. Unless there is an active
degredation or binding of IL-6 molecules between 22 and 48 hours, it is
assumed that at least an equal quantity of IL-6 remains at 48 hours and that
the decrease in IL-6 activity at 48 hours is an assay artefact.

LPS as a single agent induced a small increase in IL-6 activity in 6
hour CMs, but the level of activity remained the same over the following
42 hours. TGF-b and LPS together induced a large increase in IL-6 at 6
hours with additional, smaller increases occurring up to 22

hours.

As

discussed above, 48 hour CMs from cells exposed to both TGF-8 and LPS
apparently had less IL-6 activity than CMs from 22 hours.
The second experiment concerning the time interval 0 to 6 hours
showed that the largest increases in IL-6 activity was achieved between
hours 2.5 and 6, as presented in figure IV.xix b below. There was no

IV.xix.b. B-9 assay for IL-6 activtiy in .3% CMs collected at 0, 1, 2.5 and 6 hours after
exposure to indicated agents, are devoid of IL-6 activity. IL-1, LPS and TGF-B as single
agents fail to induce significant increases in DL-6 activity at the time points indicated. TGFB/IL-1 and TGF-B/LPS induce comparably large increases in IL-6 activity only after 6
hours of treatment. These data suggest that the greatest rate of IL-6 release by TGF-B and a
given synergen occurs between 2.5 and 6 hours of treatment. Control=media alone, EL1=10 ng/ml, LPS=1Q ng/ml, TGF-B=10 ng/ml. Negative assay control (assay cells alone)
was 8000 ^HTdR cpm of activity and the positive control (T24) was 65000 ^HTdR cpm of
activity.

detectable IL-6 activity of the CMs between hours 0 and 2.5.

As the data

from IV.xix a/b suggest, the kinetics of TGF-B synergy with LPS for IL-6
release is similar to the kinetics of TGF-B synergy with IL-1: Maximum
release is obtained between hours 2.5 and 6 of treatment, with

a large

decrease in the rate cytokine release over hours 6 through 48.

These

kinetics, summarized below in IV.xx, are also similar to the kinetics of the
above synergens for GM-CSF release (IV.vii and IV.xi) suggesting that the
effects of TGF-B for cytokine release may be achieved through common
pathways.

IV,xx. The rate of IL-6 release is at a maximum between hours 0-6, a rate
18-20 times higher than the rate of release between hours 6 & 22 and
between 22 & 48.
As presented in IV.xix.a. above, the largest increase in IL-6 release
occurs between hours 0 and 6, while
subsequent 42 hours.

smaller increases occur over the

These differences are presented in figure IV.xx

below as the rates of change in IL-6 release, or Acpm/Atime.

As

illlustrated in figure IV. xx, TGF-B and LPS induce an increase in the rate
of IL-6 release to a maximum between 0 and 6 hours of treatment . The
rate of release over the next 16 hours drops 90-95% to levels comparable
to background. Finally, the rate of IL-6 release over hours 22-48 remains
unchanged from the 6-22 hour release rate and is essentially background.
Data from figure IV.xix.b suggests that cytokine released between 0 and
6 hours is released mostly between hours 2.5 and 6 suggesting that there is
at least a 2.5 hour exposure period required before any IL-6 can be
released.

i

a

f

A cpm/ A time

Figure IV.xx. Rates of change in IL-6 release in cells exposed to TGF-B + LPS or TGF-B
+ IL-1, or single agents, for different intervals of time. The rate of change was determined
as described in III. E using the data presented in IY.xviii a. The incorporated radioactivity
in B-9 cells induced by a given sample of CM is quantitated as counts per minute (cpm).
The cpm value (Acpm) is divided by the time interval in which a given CM was produced
(Atime), either 6 hours, 22 hours, or 48 hours. The ratio of the change in cpm value of a
given CM to the dme difference between given CMs is presented as the rate of change
(Acpm/Atime) in EL-6 release.

C. STUDIES OF INTERLEUKIN-6: TGF-B and PTH

IV.xxi. Parathyroid hormone (PTH) alone does not induce IL-6 release,
but higher doses of PTH svnergize with TGF-B to induce a large increase
in IL-6 release.

Experiment IV.viii suggested that PTH had no clear

effects on osteoblast release of GM-CSF.

To determine the effect of PTH

on IL-6 release and whether TGF-B could change the profile of PTH

8 9

activity, cells were cultured with 0.02 to 20.0 nM PTH alone, TGF-B alone
(0.4 nM or with both PTH and TGF-6 (0.4 nM). As described in III.C 2,
CMs were collected after 48 hours incubation and assayed for IL-6 activity
in the B-9 hybridoma assay. Data presented below in figure IV.xxi suggest
that PTH alone does not induce IL-6 release. 2 or 20 nM PTH synergizes
with TGF-B to induce an increase in IL-6 activity in tested CMs. Note that
the effect of 2.0 nM PTH with TGF-B is largely additive for the induction
of IL-6 release.

Figure IV. xxi. B-9 assay for IL-6 activity of .3% CMs from cells cultured with either 2.0
nM or 20 nM PTH alone, or with both PTH (.02, 0.2, 2.0 or 20 nM) and TGF-B (0.4
nM). Negative experimental control (0) is included. Negative and positive (1.0 % T24
CM) assay controls were 4 x 103 3H-TdR cpm and 45 x 103 3H-TdR cpm, respectively.

IV. xxii. PTH/TGF-B synergy for IL-6 release may be TGF-B dependent.
As described in III. B, a series of 'priming' experiments were done in
which osteoblasts were exposed to TGF-B alone for two hours at a
concentration of 400 pM. The cells were then washed, and then incubated
with PTH (.20, 2.0 or 20 nM) for the next 46 hours.

The converse

experiment, namely PTH 'priming' followed by TGF-B exposure, was not
performed. As shown below in figure IV.xxii, there was no IL-6 activity
in CMs from cells cultured with TGF-B alone for hours 0-2, and then with
fresh media alone for hours 2-48.

However, cells incubated with TGF-B

for hours 0-2 and then PTH for hours 2-48 produced CMs with the high
IL-6 activity seen in previous experiments.
3HTdR cpm x 10“3

Figure IV.xxii. B-9 assay for EL-6 activity in a series of 'priming' experiments. Agents
were added to cell cultures for the period of time as indicated. Experimental control is
included. Negative and positive (1.0 % T24 CM) assay controls were 4 x 103 3H-TdR
and 45 x 103 3H-TdR cpm, respectively. CMs asayed at a .3% dilution.
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C. STUDIES OF M-CSF

IV. xxiii. TGF-B does not stimulate the secretion of M-CSF. As described
in III.B, osteoblasts were cultured in media alone or in media with TGF-B
at three different concentrations, 0.1 ng/ml, 1.0 ng/ml or 10 ng/ml. CMs
were collected and assayed for Macrophage-CSF (M-CSF) using the BAC
M-CSF-dependent macrophage line.

Figure xxiii. BAC cell assay for M-CSF activity of CMs from osteoblasts cultured with one
of three concentrations of TGF-B: 100 pg/ml, 1.0 ng/ml, or 10 ng/ml. The abcissal values
correspond to the counts per minute of incorporated tritiated thymidine by the BAC cells in
the M-CSF assay. The ordinate values are indicated per diagram. Assay positive (10 %
L929 CM) and negative controls are included while the experimental control (10 % media
alone) value was 26 x 103 3H-TdR cpm.

\
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As presented in figure IV.xxiii above, TGF-B at the concentrations tested
did not induce any M-CSF release from osteoblasts detectable in the CMs

IV.xxiv.

TGF-B and LPS fail to svnergize for M-CSF release from

osteoblasts.

Osteoblasts were cultured with either TGF-B, LPS, or TGF-B

and LPS together as described in section III. B. CMs were tested for MCSF activity as outlined above and in table ffl.i. As presented in figure IV.
xxiv below, 100 ng/ml LPS induced M-CSF activity in tested CMs as
reported previously87.

However, TGF-B had little or no effect on the

osteoblast response to either dose of LPS for M-CSF release.

Figure IV.xxiv. BAC cell assay for M-CSF showing relative amounts of activity of tested
CMs. • =TGF-B at 10 ng/ml, ♦= LPS 10 ng/ml, 0= LPS 100 ng/ml,■= TGF-B at 10
ng/ml + LPS at 10 ng/ml,D= TGF-B at 10 ng/ml + LPS at 100 ng/ml. The abcissal values
correspond to the counts per minute of incorporated tritiated thymidine by the BAC cells in
the M-CSF assay. The ordinate values are indicated as % CM tested. The negative and
positive (10 % L929 CM) assay control values were 14 and 135 x 103 3H-TdR cpm,
respectively. The negative experimental control (media alone) value was 22 x 103 3H-TdR
cpm.
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D. BONE MARROW INDUCTION STUDIES

IV. xxv. TGF-Beta and IL-1 do not induce the proliferation of total bone
marrow cells from C3H/HeJ mice. As described in III. A, bone marrow
cells were obtained from the long bones of C3H/HeJ mice. C3H-HeJ mice
carry a recessive gene which renders them unable to respond to most forms
of lipopolysaccharide (M. Horowitz, personal communication). C3H/HeJ
cells were therefore selected to test any stimulatory effect of LPS on the
assay cells described in IV.A-C and to test the effect of LPS and TGF-B

MTdR cpm x 10

on total marrow populations. Marrow cells were

Figure IV.xxv. 12 hour incorporation of tritiated thymidine by C3H/HeJ marrow cells
during exposure to CMs from experiment IV.xxiii. Ordinate values are indicated.
Negative (0) and positive (+C:i929) assay control groups are indicated.
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cultured with TGF-Beta (10 ng/ml), with LPS (10-1000 ng/ml) or with
both agents together. As shown in figure IV.xxv above, the marrow cells
exposed to both TGF-B and any concentration of LPS showed a small
increase in proliferation over control groups as measured by uptake of
tritiated thymidine. The additive effect of LPS and TGF-B for marrow cell
proliferation is less the synergistic effects of LPS and TGF-B presented in
previous sections. One may note, however, that the present experiment
utilized total marrow populations and not specific assay cells (i.e. HT-2)
responsive to a limited number of cytokines. The marrow population
contains all cell types- the number of cells represented which are
responsive to TGF-B/LPS-induced cytokines may be too small to mount an
observably high increase in proliferation

E. STUDIES WITH PLATELET-DERIVED GROWTH FACTOR
IV. xxvi. PDGF and IL-1 svnergize to increase GM-CSF production.
TGF-B may control the bimodal growth response of osteoblasts to
the hormone via the autocrine elaboration of PDGF-AA, -AB, and/or -BB
and the control of the PDGF receptor102,103#

has been found to

influence mitogenesis of fibroblasts and smooth muscle cells (SMCs) by an
analogous induction of PDGF release. Osteoblasts are known secretors of
PDGF-BB but express receptors for both PDGF-AA and PDGF-BB.

It

was hypothesized that the synergy between TGF-B and IL-1 for cytokine
release may be due to an autocrine PDGF loop. To test the hypothesis,
osteoblasts were cultured in media alone, with PDGF-AA, with PDGF-BB,
with IL-1 or with IL-1 plus one of the two PDGF isoforms. CMs were
assayed for GM-CSF activity. Data presented below in figure IV. xxvi

show that IL-1 and PDGF-BB synergized to enhance GM-CSF release
from osteoblasts but the effects of IL-1 and PDGF-AA was not as
pronounced.

%CM

Figure IV. xxvi. HT-2 assay for GM-CSF activity: Effects of IL-1 and PDGF isoforms
on the release of three cytolanes from osteoblasts. 0= assay control, 0=IL-1 10 ng/ml,
A=PDGF-AA 10 ng/ml, [j]=PDGF-BB 10 ng/ml, #=IL-1 + PDGF-AA each 10 ng/ml,
■=IL-1 + PDGF-BB each 10 ng/ml. Negative and positive (10% rh-IL-2) controls had
values of 0.7 x 10-3 3H-TdR cpm and 95.0 x 10-3 3H-TdR cpm , respectively. CMs
tested at .3% dilution.

V. DISCUSSION Summary of findings; Possible
mechanisms of TGF-B synergy and roles in bone remodeling and hematopoesis;
Unifying concepts of TGF-B in cell biology; Future studies

Normal bone remodeling is a dynamic process in which the
concerted action of osteoblasts and osteoclasts can replace the entire
human skeleton with new bone in less than three years.
bone formation requires the osteoblast

Normal

to regulate its growth, to

respond appropriately to extracellular signals and to function
cooperatively among a population of other cells.

Abnormal bone

formation and bone disease is the result of defects in these processes.
The complexity of normal bone formation and the difficulty of
understanding the process of bone disease may be appreciated by the
gross examination of pathologic specimens of bone. The following
case of osteomyelitis from the American Civil War is particularly
striking, as the severity of disease is seldom seen in today's world of
antibiotics.
On 15 June, 1865,

Corporal Walter Ford of the 1st United

States Colored Troops was wounded in the left leg by a 1/4 inch ball
fired in an antebellum incident in Petersburg, Virginia.

Taken to a

Baltimore hospital, the 20 year-old Ford struggled with erysipelas, a
recurrent wound infection and "continual pain"*. The corporal
eventually died of "general fatty degeneration and leukocythaemia"*
in February of 1866.

Army surgeons had been collecting

traumatized bone specimens throughout the war to medically
categorize the spectrum of war injuries and so preserved Ford's left
femur, now in permanent storage at the Army Medical Museum in
Washington, D.C. As shown in figure V.i a below, the femur was
*U.S. Army Surgeon's Report, 1882

'
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was fractured completely midshaft. An irregular bone callous joined
the proximal ends with disorganised, abnormal bone occurring in
areas far from the immediate trauma locus. In contrast, in figure

Figure V.i.a. Left femur of Corporal Walter Ford, 1st United States Colored
Troops, who sustained a "shot fracture" of the leg in June, 1865, suffered months
with recurrent infections and eventually succumbed in February, 1866. The
haphazard and irregular bone formation typical of osteomyelitic remodeling which
produces a brittle, porous bone. Photograph courtesy of the Department of
Defense, Armed Forces Institute of Pathology.

V.i.b, is the normal bone formation of a similar fracture of the right
femur from a Peruvian male dated circa 2000 B.C. Corporal Ford’s
case is important in that it addresses aspects of bone biology essential
to this thesis: First, what signals do osteoblasts use to form bone in a
regulated, polarized fashion

in normal or traumatic bone

remodeling? Second, how can such signals be changed in an infected

locus to produce distorted, haphazard bone? And third, are defects
in these processes important in the development of bone diseases and
cancer?

A better understanding of these challenging issues may

Figure V.i.b. Right femur of a Peruvian male, dated 2000 B.C. Fracture most
likely the result of blunt injury or fall, suggesting the wound was closed and sterile.
The presumably aseptic fracture has been healed by a regular, organized process of
bone remodeling in marked contrast with that of figure V.i.a. Photograph courtesy
of the Department of Defense, Armed Forces Institute of Pathology.

come since the discovery of several unique endocrine properties of
the normal osteoblast and its environ:
It has been recently demonstrated that osteoblasts are among the
body's

most active producers of cytokines, a hormone class

implicated in the control of hematopoesis and other growth
processes. Osteoblast cytokine production has been studied for roles
in bone metabolism and in fracture healing, but a definitive role for
cytokines in bone remodeling is not yet

clear29,87<
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Transforming Growth Factor-Beta (TGF-B) is a platelet-derived
hormone which is stored in the matrix of bone. TGF-B is a pleotropic
protein whose actions range from immunosuppression to matrix
upregulation167.

This thesis presents experiments which studied the

effects of TGF-B on osteoblast cytokine release in vitro.

We present

evidence that TGF-B has multiple effects upon osteoblast cytokine release
which can be summarized below and in figure V.ii:

(1) TGF-B induces IL-6 but not

GM-CSF release

from osteoblast in vitro.
(2) Parathyroid hormone

(PTH),

and low dose

lipopolysaccharide (LPS) and Interleukin-1 (IL-1) are
not inducers of cytokine release from osteoblasts in
vitro.

(3) TGF-B synergizes with low dose LPS* or IL-1*
to induce the secretion of both GM-CSF and IL-6
from osteoblasts in vitro.
(4) TGF-B synergizes with PTH* to induce the release
of IL-6 from osteoblasts in vitro.
(5) The enhanced cytokine production by TGF-B and
a synergen is not ablated by indomethacin.
(6) TGF-B functions to "prime" osteoblasts to respond
to LPS and PTH.
(7) The rate of cytokine release is at

a maximum

between 0 and 6 hours after exposure to TGF-B and a
*Any molecule discussed in this thesis which synergizes with TGF-B for cytokine
release will, for clarity, be referred to as a synergen.
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synergen. The rate of cytokine release falls to baseline
thereafter.
(8) TGF-6

fails to upregulate the release of M-CSF

from osteoblasts in vitro and does not enhance LPSinduced release of M-CSF.

These experiments are the first to characterize a synergistic
relationship

between TGF-6 and other molecules to enhance

cytokine release from bone cells.
Furthermore, this is one of the first reports of an ability of
TGF-6 to upregulate cytokine release from any cell type. The
observations are unusual in that TGF-6 has previously been regarded
as a negative growth regulator and as an immunosuppressive agent.

Figure V.ii. Effects of TGF-6 and various synergens on osteoblast cytokine
release. TGF-6 and PTH will synergize to induce the release of IL-6 from
osteoblasts. TGF-6 can also synergize with either IL-1 or LPS to induce the release
of IL-6 as well as GM-CSF.
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Its ability, however, to upregulate fibroblast matrix formation and to
induce neoplastic growth in normal fibroblasts underlies the
pluripotent affects of TGF-B on cell biology.
According to the data presented in this thesis, TGF-B confers
upon osteoblasts the ability to respond to several unrelated molecules
in a similar way with greatly upregulated cytokine release.

The

characteristics of each response, however, suggest that osteoblasts
respond to TGF-B in a regulated, hormone-specific manner, and that
the response is important to the cell as it is preserved even after 24
hours of serum deprivation. These hypotheses are supported by data
which are discussed separately in the following sections: Cell Purity,
Cell Dormancy and Reactivation, Response Rapidity, Cytokine
Specificity, TGF-B dependence, Mechanisms of Synergy, and New
Elements of Bone Remodeling and Hematopoesis.

Cell Purity.

No method

in the contemporary literature

achieves cell cultures from bone which are 100% osteoblasts. The
extraction procedure by Wong et al.208, however, produces
osteoblast cultures with 95% purity as determined by analyses of
specific protein marker profiles33*3.

Wong et al. employed

a

collagenase digestion technique to isolate fetal osteoblasts and is the
protocol used in this thesis.

Known contaminating cells include

fibroblasts and tissue macrophages.

Fibroblasts are known

producers of some cytokines. The fibroblast contribution to the
magnitude of cytokine release observed in these experiments may be
small, based on the actual number of such cells identified in
osteoblast preparations33*3’208. Macrophages, however, despite low

numbers, can secrete Interleukin-1, which may potently alter the
osteoblast response to TGF-B.

To test this possibility, all CMs

assayed were analyzed for inherent Interleukin-1 activity as
described in III. A and C using the LBRM assay. No significant IL-1
activity was detected in any conditioned medium from cultured
osteoblasts, regardless of the type of added stimulatory reagent (data
not presented). The sensitivity of the LBRM assay allows a
determination of IL-1 activity from concentrations as small as 10
pg/ml (Horowitz, M., pers. comm, and Zltonik et al.213b). The
cultures of osteoblasts used in these studies were, therefore,
relatively pure. The cytokine activity of each tested CM was most
likely derived from osteoblast activity and not from contaminating
co-inhabitants of fetal rat parietal bone.

Cell Dormancy and Reactivation. As discussed in section II. B,
all osteoblasts cultured for these studies were serum-deprived in
vitro for 24 hours in media alone prior to experimentation.

Cells

cannot grow in vitro in serum-deprived media, but will survive for
periods of time. Normal cells respond to the serum-deprived state
by shutting off cellular activities

not essential towards the

maintainence of basic cellular integrity. Serum-deprived cells leave
the active cell cycle and enter the Go phase of cell life- a
'housekeeping' period of dormancy in which there exists minimal
energy expenditure, gene activity or protein production.

Our

observation that TGF-B induces cytokine release in such dormant
cells suggests that the ability to produce and release cytokines is
preferentially maintained in the Go osteoblast and that TGF-B may be
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an important hormone for activation of this response in vivo. What
remains to be determined is the importance of cytokines, and the
rapid upregulation of cytokine production in the quiescent osteoblast.

Response Rapidity. Preliminary experiments tested CMs from
osteoblasts cultured with TGF-B and LPS after 48 hours of exposure.
To obtain a more complete response curve, additional experiments
analyzed CMs from osteoblasts after 1, 2, 6, 12 and 48 hours of
exposure to TGF-B and LPS. As presented in figures IV.vi.a/b and
xix a/b, data revealed that 95% of the GM-CSF and IL-6 activity
found in the CMs after 48 hours of exposure was found in 6-hour
CMs

but not in

2.5-hour CMs.

The relative rates of cytokine

release over the five timepoints were determined as the ratio of the
change in cytokine cell-proliferating activity (A CPM) to the change
in time (At) and presented in figures IV. vii and xx.

The rate of

release for both GM-CSF and IL-6 is at a maximum from hours zero
to six.

From 6-22 hours, the release rate drops 75-90% and from

22-48 hours, the rate returns to near baseline values. These results
suggest that the effect achieved by TGF-B and a given synergen on
GM-CSF or IL-6 release is rapid and short-lasting.

How and why

the osteoblast maintains secretory pathways to respond quickly after
appropriate stimulus, even after 48 hours of serum-deprivation, is
not clear.

Cytokine Specificity
cytokine hormones:

Osteoblasts are known to secrete three

two colony stimulating factors (M-CSF and

GM-CSF) and Interleukin-6 (IL-6). All three molecules were tested

105

in CMs derived from stimulated osteoblasts. Only two of the three,
GM-CSF and IL-6, were affected by TGF-B stimulation with a given
synergen, either IL-1 of LPS. PTH was a unique synergen in that
TGF-B/PTH elevated the release of IL-6 but did not change the
release of GM-CSF (Figures V.ii).

The release of the third

osteoblast-derived cytokine, M-CSF, was not changed by the TGFB/synergen combinations studied.

The interchangeability of LPS

and IL-1 as synergens for TGF-B stimulation suggest that LPS and
IL-1 may utilize similar intracellular pathways of activation in
concert with those utilized by TGF-B.

PTH, however, may utilize

still other pathways to specify release of IL-6.

Several questions

arise. First, how do the roles of the cytokines differ in the local
environment when IL-6 is released singly (TGF-B + PTH) or in
combination with GM-CSF (TGF-B + IL-1 or TGF-B + LPS)?
Second, what is the significance of the

exclusion of M-CSF from

these reactions, besides the assumption that its release utilizes
pathways unaffected by TGF-B.

Would the

release of M-CSF in

addition to the other hematopoetic cytokines be a biologic
redundancy or counteract the effects of these other molecules? The
described roles of M-CSF in bone biology are limited but include a
role as growth promoter for osteoclasts12813’206’212. GM-CSF and
IL-6 may function to upregulate osteoblast activities which could be
lessened by M-CSF-induced osteo clast activity.

Dependence of Synergy on TGF-B

A set of 'priming'

experiments were conducted in which cells were exposed to TGF-B
for two hours, washed, and exposed to LPS. Conversely, other cells
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were exposed to LPS as the 'priming' agent, washed, and then
exposed to TGF-B. Results from figures IV.v and xvi demonstrate
that the increases in cytokine release previously observed were
duplicated when cells were initially exposed to TGF-B and then to
LPS. Little or no increase in cytokine release was seen when cells
were first exposed to LPS and then to TGF-B.

Cells could also be

primed for IL-6 release by TGF-B with subsequent exposure to PTH
(Figure IV. xxii).
These observations suggest that the synergy between TGF-B
and a given synergen for cytokine release may be dependent upon
TGF-B itself. TGF-B may possibly function to prepare the osteoblast
to respond to a secondary stimulus, such as LPS or PTH, with large
releases of active cytokine. Studies with TGF-B as a cell primer for
IL-1 are to be performed.

Clearly, any effect that TGF-B imparts

upon the cell lasts long enough to augment the stimulatory effect of a
subsequent agent. What enables TGF-B to 'prime' the osteoblast for
cytokine release is not clear.

Mechanisms of Synergy.

It is difficult to determine the roles

of TGF-B in osteoblast stimulation and those of a given synergen but
some assumptions may be made.

First,

activation of the cell by

TGF-B may utilize pathways different than those of LPS or PTH
since cells can be 'primed' by TGF-B and not by these two synergens.
Second, activation of the TGF-B-mediated pathway(s) is the ratelimiting step in cytokine release since the process is TGF-B
dependent.

Third, the pathways utilized by TGF-B in enhancing
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cytokine release must be readily activated, within hours of exposure,
to high levels, even in the serum-deprived state.
Three hypotheses arise which may unite the observations
presented above concerning the role of TGF-B and its synergens in
cytokine secretion: (1) TGF-B functions to upregulate the number
or activity of surface receptors for a given synergen;

(2) TGF-B

functions to upregulate second messenger systems common to TGFB and its synergens; and (3) TGF-B induces the release of PlateletDerived Growth Factor (PDGF) which, in turn,
osteoblast in concert with another synergen.

activates the

Each hypothesis is

supported by data in the present work and data in the literature and
will be briefly discussed as follows.

a. Upregulation of synergen surface receptors by TGF-B.
A qualitative analysis of osteoblast IL-1 receptor mRNA was
performed in which cells were exposed to TGF-B, a synergen, and to
both agents together. The results presented in figure IV. xii suggest
that osteoblasts exposed to TGF-B have more mRNA for the surface
receptor for Interleukin-1 (IL-1R) than control cells. The messsage
level is unchanged by IL-1 itself.

This is in contrast with the

fibroblast studies by Dubois et al.54 who found that TGF-B
suppressed fibroblast expression of IL-1R. Transcriptional studies
will determine whether this affect is secondary to enhanced mRNA
stabilization or to increased message synthesis. If TGF-B enhances
expression of functional IL-1R, it remains unclear what pathways the
IL-1R activates for cytokine release. The synergy between TGF-B
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and IL-1 for GM-CSF release may, therefore, be a two-step process
in which TGF-B first increases IL-1R levels allowing the cell to
respond to a previously sub-stimulatory level of IL-1 (Figure
V.iii.a).

Increased osteoblast sensitivity to IL-1 may be particularly

important for the cell's response to early infection when local IL-1
levels are low.

b. Upregulation of svnergen second messenger systems by
TGF-B.
TGF-6 may function to 'prime'

cells by activating second

messenger systems from quiescence or baseline state.

The TGF-B

receptor may act to upregulate proteins maintained in the quiescent
state for the trans-activation of a broad range of regulated genes.
Alternatively, TGF-B may simply enhance a rate-limiting step for
second messenger production by a synergen102.
Most growth factors induce the production of second
messenger signals, like diacylglycerol (DAG) and intracellular
calcium

([Ca+ + ]i), by enhancing phosphotidylinsoitol

turnover168.

(PI)

Cells can be stimulated by agents which substitute for

DAG and [Ca++]i, such as phorbol esters and calcium ionophores,
resepectively138d50> pi turnover may not be the sole mechanism to
achieve this end.

Many primary cells require two growth factor

signals- one that enhances PI turnover and one that does not168. Tcells, for example, proliferate maximally only after co-stimulation
by antigen and IL-1.

Antigen increases PI turnover but IL-1 does

not. As presented in II. B, Rosoff et al. showed that IL-1 stimulates
the production of another phospholipid, phosphotidylcholine
(PC)168.

PC hydrolysis produces a species of diacylglycerol (DAG)

!

,
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distinct from DAGs produced after PI hydrolysis.

As shown in

figure II. ix, the two DAG species activate species-specific kinases
which synergize to activate transcription factors.
TGF-6 may prime osteoblasts to respond to IL-1 by enhancing
IL-1- specific DAG production or DAG-dependent kinase activity
from baseline state. This would allow the rapid up-regulation of
second messenger systems while maintaining the specificity of IL-1induced pathways. Alternatively, TGF-B may itself produce DAGspecies which synergize with those derived after IL-1 stimulation for
protein kinase C activation.
The second messenger pathways important in LPS activation
of the cell are not as well-characterized as IL-1, but most likely
involve hydrolysis of the cyclic nucleotides, cAMP or cGMP“d,61
TGF-B may function to upregulate the activity of the second
messenger system by enhancing or activating distal enzymes such as
protein kinase C or A or other LPS-specific serine kinases.
The 'priming' of the cell by TGF-B,

as discussed above,

would correspond to the rapid activation by TGF-B of rate-limiting
steps in second messenger systems. Subsequent ligand binding by a
synergen would then utilize the activated second messenger system
for full cell stimulation and cytokine production. Second messenger
upregulation by TGF-B would provide for a rapid, efficient process
of specific kinase activation without the need for transcriptive or
translative processes.
r. PDGF as a mediator of TGF-B/svnergen
osteoblasts.

stimulation

of

Workers have shown that a TGF-B-controlled autocrine loop
exists involving Platelet-derived Growth Factor (PDGF)1°>95: Low

levels of TGF-B upregulate PDGF-AA release from smooth muscle
cells and high TGF-B levels downregulate PDGF-a receptors. The
combined effect may explain in part the bimodal effect on cellular
growth seen over a range of TGF-B concentrations in

TGF-P

Figure V.iii. Hypothetical activation sequences of TGF-B synergy with IL-1 for
cytokine release, a) TGF-B ligand induces post-receptor events which upregulates
cytoplasmic and/or nuclear events for cell priming. TGF-B-induced events lead to
bi) upregulation of receptors for IL-1 and/or b2) production of PDGF. In the latter
hypothesis depicted in figure b2, IL-1 synergizes with autocrine PDGF dimer. The
result of either bi or b2 leads to c) cytokine release. Adapted from concept by
Palumbo et al. (with permission)154.
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fibroblasts, smooth muscle cells, chondrocytes, and

67

osteoblasts34’1

Like TGF-6, IL-1 -induced mitogenesis has also been found to
involve autocrine production of PDGF-AA160 and modulated by
TGF-6155.
PDGF exists in

isoform mixtures derived from the three

possible combinations of hormone subunits, A and B: A A, AB, or
BB.

Isoform AA is a ligand for a-type PDGF receptors and

isoforms AB and BB are ligands for 6-type receptors. The PDGF A
chain is efficiently secreted and is a potent inducer of cytokine
production in fibroblasts103’1!9. The B chain remains cell associated,
has a 25-fold higher transforming ability for fibroblasts, and is the
homolog of the v-sis oncogene product.

Osteosarcoma cells

translate both PDGF-A and -B mRNA (c-sis) into processed
polypeptide whereas normal human and rat osteoblasts produce only
PDGF-A A71,72,81,

implicating PDGF-BB and v-sis in neoplastic

bone cell growth.

In bone cell studies, PDGF-BB enhances

osteoblast chemotaxis190, DNA synthesis and replication36, collagen
synthesis and bone formation34’159. PDGF-AA has lower activity in
these studies than AB or BB isoforms.
Centrella et al. have shown that osteoblast PDGF receptors
preferentially bind PDGF-BB over -AA although osteoblasts
produce mostly the PDGF-AA isoform37,38a# This phenomenon is
most likely a consequence of PDGF receptor type expression by the
osteoblast, type 6 > a. IL-1 a, however, can increase PDGF-AA
binding

to induce levels of mitogenesis equivalent to levels induced

by PDGF-BB386.

PDGF-AA action on osteoblasts may be thus

controlled by other local factors.

Released PDGF-AA induces the oligomerization of cell surface
receptors for other PDGF ligands and the oligomerized receptors
synergize for tyosine kinase activity!7**. Multiple post-receptor
events are complex and involve a physical association with four other
enzymes including

phospholipase C gamma (PLC-y)115,122^

phosphatidyl inositol 3-phosphate kinase (PI-3pK)5, the serinethreonine kinase raf-l1^ and GTPase Activating Protein
(GAP) 103. TGF-B and IL-1 may thus synergize by converging on
common PDGF-signalling pathways upregulated by TGF-B priming
and enhanced further by IL-1 activation.
To identify a role of

PDGF expression in the synergistic

elaboration of cytokines by TGF-B and IL-1, osteoblasts were
exposed to IL-1 and PDGF-AA or PDGF-BB with the appropriate
controls. As presented in figure IV. xxiv,

PDGF-BB

synergized

with IL-1 for GM-CSF release from osteoblasts. Production of IL6 was not assayed. The effect of PDGF-AA with IL-1 was less than
the effect of PDGF-BB.

Experiments in which osteoblasts are

exposed to both TGF-B and IL-1 but in the presence of antibody to
the PDGF-BB ligand and/or receptor are to be performed. Such an
experiment would be likely to determine the role of PDGF-BB in
TGF-B mediated cytokine enhancement.
Cytokine release induced by TGF-B and a synergen from
previous experiments occurs within 6 hours. It is unclear how TGFB induces PDGF release and how IL-1 and PDGF then induce
cytokine release within a 6 hour time frame.
Two distinct growth factor signals are often required for cell
stimulation. Fibroblasts can be stimulated by PDGF, which enhances
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phosphotidylinositol turnover, if the cells are also exposed to a
growth factor which does not enhance PI turnover168. As discussed
in V.vi.b, such a ’second molecule' may be IL-1.

PDGF and IL-1

may, therefore, synergize for cytokine release by activating two
separate pathways of cell stimulation which converge upon a
common point for cytokine production, i.e. a transcription factor.
It remains to be determined if PDGF may be significant in
mediating the synergy between TGF-B and LPS or between TGF-B
and PTH.

Common Themes of TGF-B Activity. The hypotheses discussed
above and presented in figure V. iii suggest that TGF-B acts as an
early signal for generalized activation of the dormant cell. As
presented in figure V. iv, TGF-B may initially activate a cell from
quiescence while the cell’s ultimate response is determined by the
presence of other serum growth factors.

TGF-B was originally

described as a transforming growth factor with such a role, as
discussed in II. A. TGF-B, isolated from neoplastic cells in vitro,
was observed to facilitate the transition from Go to Gi in normal
cells and eventually induced neoplastic growth in cells exposed to
PDGF-BB, EGF, and IGF-191.

In normal conditions, as in the

osteoblast studied in this work, TGF-B may be one of a few
extracellular molecules, present in semm, which maintains the cell in
the activated state. The absence of TGF-B from the extracellular
mileau could imply the absence of other nutrients as well. The
absence of TGF-B allows the cell to become quiescent and conserve
metabolism in periods of nutrient scarcity. The presence of TGF-B,
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however, would enable the cell to respond to other signals for
structural

protein

synthesis,

mitosis,

or cytokine

release.

Considering the rapidity of cytokine release from the dormant cell, it
is unclear if cytokines are important only as paracrine growth
factors, or are important as autocrines in the processes of cell
reactivation.
These hypotheses do not consider the source of released
cytokine. Translational inhibition studies would quickly determine
whether new cytokine is

produced or stored cytokine is released

following cell stimulation.

The latter possibility seems unlikely

unless cytokines are so significant to the cell that they are stored for
long periods in the dormant cell, ready for release when the cell is
appropriately stimulated.

New Elements in Bone Remodeling and Hematopoesis. The
role of TGF-B and its synergens in cytokine release by osteoblasts
remains unclear. Perhaps, as implicated above, TGF-B functions as a
cell 'activator', enhancing second messenger or receptor systems
utilized by synergens (Figure V.iv). The roles for TGF-B and its
synergens may elude scientific determination for some time, but the
effect of these molecules is clear: greatly increased cytokine release.
As suggested previously, such a response may be important to the
newly resuscitated cell since cytokine release is maximally observed
less than 6 hours after stimulation from quiescence. What remains
is to determine how cytokine release is important to the osteoblast,
and what roles released cytokines may play in normal growth
processes. Possible clues are suggested with analysis of the anatomy

and biology of bone remodeling.

Osteoblasts, the bone-forming

cells, are situated in close proximity to the osteoclasts, the boneresorptive cells, and to osteoclast resorptive pits or lacunae. Situated
close to these cells, and adjacent to and supported by the bone matrix

Figure V.iv. Common role of TGF-B in cell activation. A common concept for
TGF-B's roles in growth transformation, matrix formation, and cytokine release
may be that TGF-B functions to induce changes in the Go cell. These intracellular
changes alone are insufficient to induce protein release but act to 'prime' the cell to
respond to a secondary growth signal.

itself, lies the bone marrow. Given the observations presented in this
thesis, a possible model arises concerning the role of TGF-B and its
synergens in bone remodeling and hematopoesis itself: As depicted
in figure V.v, osteoclasts resorb bone and release from the matrix
inactive TGF-B, as described on paes 12-13. The protons used by the
osteoclast to resorb bone accumulate in the pit, and this low pH,
combined with osteoclast enzymes, activates latent TGF-B.

The

active TGF-B diffuses the short distance to the osteoblast and binds to
the TGF-B receptor.

Meanwhile, parathyroid hormone which has

diffused into the remodeling locus, stimulates PTH receptors on the
same osteoblast.

The TGF-B and the PTH synergize to induce

osteoblast production of Interleukin-6.

The IL-6 diffuses back and

may enhance osteoclast resorptive activity, or diffuse across the

resorptive locus and enter the bone marrow to induce IL-6dependent marrow lines (B-cells)64.
Other models arise when osteomyelitis or a fracture locus is

BONE

MARROW

Figure V.v. Model for osteoblast cytokine release at the resorption locus, as
described below, for TGF-B and IL-1 synergy.

superimposed upon normal remodeling.

Active infections, for

example, would provide IL-1 from recruited bone and blood

macrophages.

IL-1 would synergize with TGF-8 to release both

GM-CSF as well as IL-6, an effect perhaps mediated by PDGF. The
GM-CSF could diffuse into the marrow space and induce the growth
of and act as a chemoattractant for neutrophilic and monocytic lines.
These cells may

migrate into the remodeling locus to focus and

augment the processes of bone healing from infection or trauma.
Gram-negative bacterial osteomyelitis would also provide LPS, the
active component of endotoxin, providing another synergen for
TGF-8 dependent cytokine release.

Continuous stimulation of

cytokine production by exogenous LPS and LPS-induced IL-1
release may

ablate local control and feedback mechanisms in

cytokine-mediated bone remodeling. Haphazard osteoclast and
osteoblast activity may give rise to bone with the classic
characteristics of unchecked and untreated osteomyelitis as seen in in
figure V.i.
Bone fracture, however, with accompanying hemorrhage and
clot, would provide many molecules of PDGF-AB and BB, which
may mediate many of the effects of TGF-13 for GM-CSF and IL-6
production.

TGF-13-induced osteoblast activity may also lead to

increased osteoid formation and bone repair 157.
With several ways to provide GM-CSF and IL-6, TGF-8 and its
synergens

could enhance the healing changes

osteomyelitic and fractured mineralized tissue.

required in

What arises from

these models is an impression that the local environment of the bone
remodeling locus is intimately regulated on the local level by
processes initiated by TGF-8. Whether in the pathologic conditions
of trauma or osteomyeltis, or in normal bone remodeling, TGF-8
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may be an important mediator between osteoclasts, osteoblasts, and
cell lines of the bone marrow.
There is some evidence in the literature that supports the
hypothesis that osteoblast-derived cytokines may be important in the
support of normal hematopoetic processes in the bone marrow43’87.
The evidence presented in this thesis suggests that TGF-B may be an
important molecule in the normal control of such a relationship
between the stromal cell of the bone matrix (osteoblasts) and stromal
cells of the bone marrow (stem cells).
Cytokines doubtless evolved in cells which were dependent upon
other cells for survival.

Paracrine hormone activity most likely

existed long before the multi-organ relationships in endocrine
activity since the first complex 'organisms' were most likely two- or
three-celled. The multi-cellular construction of the body increases
the importance of paracrine relationships since the diverse biological
activites of each cell type may be intimately controlled on the local
level. Osteoblasts are no different than other cells in that osteoblasts
regulate normal growth and function by responding appropriately to
extracellular signals. Cytokines may be important molecules in the
paracrine orchestration of cellular activity and growth in a localized
area.

The evidence presented in this thesis further implicates

cytokines and TGF-J3 in local control mechanisms. What remains to
be determined is the significance of such activities in normal bone
biology and how these activities are involved in the pathogenesis of
bone disorders.
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